The QualityStocks Daily Thursday, August 22nd, 2019

Today's Top 3 Investment Newsletters

QualityStocks (DLYT) +154.78%

SmallCapRelations (NETE) +61.21%

MissionIR (PBIO) +38.02%

The QualityStocks Daily Stock List

Pulse Seismic, Inc. (PLSDF)

Stock Picks Daily, StreetWise Reports, TeleTrader, MicroSmallCap, Global Banking & Finance Review, Stockhouse, Seeking Alpha, TMXmoney, Wallet Investor, and GlobeNewswire reported earlier on Pulse Seismic, Inc. (PLSDF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Pulse Seismic, Inc. is a market leader in the acquisition, marketing and licensing of 2D and 3D seismic data to the western Canadian energy sector. The Company owns the largest licensable seismic data library in Canada. The data library offers oil and natural gas producers roughly 65,310 net square kilometers of 3D data and 829,207 net kilometers of 2D data. OTCQX listed and established in 1985, Pulse Seismic is based in Calgary, Alberta.

The seismic data library extensively covers the Western Canada Sedimentary Basin. This Basin is where the majority of Canada’s oil and natural gas exploration and development take place. More specifically, the library covers key areas in Alberta, Northeast British Columbia and Saskatchewan, and includes portions of the Northwest Territories, Yukon, Manitoba and Montana.

Pulse Seismic continually expands its data library by purchasing data from diverse sources, such as seismic acquisition companies and exploration companies. The Company also expands its library through adding new data acquired via participation surveys. Most of Pulse’s data sets cover the full range of prospective geological zones, unlike some data sets that concentrate on particular targets at specific depths. Every data set within the Company’s seismic library is usually available for a quality inspection and delivery within 24 hours.

Recently, Pulse Seismic announced it completed a $7.0 million sale of 3D seismic data. The sale consists of a transaction-based obligation along with a new licence for additional 3D data. The corporate acquisition of Seitel Canada Ltd. on January 15, 2019 more than doubled Pulse’s seismic coverage, increasing the Company’s revenue-generating potential by adding innovative, complementary, high-quality data over areas that Pulse’s library did not previously cover.

Pulse Seismic’s Data Library Sales Revenue was $10.6 million for the three months ended June 30, 2019 versus $1.9 million for the three months ended June 30, 2018. Data Library Sales Revenue was $15.9 million for the six months ended June 30, 2019 versus $4.2 million for the six months ended June 30, 2018.

Pulse Seismic, Inc. (PLSDF), closed Thursday's trading session at $1.62, up 4.5161%, on 600 volume with 3 trades. The average volume for the last 3 months is 4,525 and the stock's 52-week low/high is $0.995199978/$1.92999994.

chart

Ascent Capital Group, Inc. (ASCMB)

TeleTrader, Real Investment Advice, Investing.com, Wallet Investor, Otc.watch, 4-Traders, Morningstar, GuruFocus, Stockwatch, GlobeNewswire and Market Screener reported on Ascent Capital Group, Inc. (ASCMB), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

Ascent Capital Group, Inc. is a holding company whose chief subsidiary is Monitronics International d/b/a Brinks Home Security™, one of the largest home security and alarm monitoring companies in the United States. Monitronics secures roughly 900,000 residential and commercial customers. It markets and sells its products via a network of authorized dealers. Listed on the OTC Markets and incorporated in 2008, Ascent Capital Group is headquartered in the Dallas-Fort Worth area of Texas.

The Company has the nation’s largest network of independent authorized dealers, providing products and support to customers in the United States, Canada and Puerto Rico, and also direct-to-consumer sales of DIY and professionally installed products. Ascent Capital Group and Monitronics International’s affiliation with The Brink’s Company is that of a license agreement by and between The Brink’s Company and Monitronics International. The Brink’s Company is not an investor in Monitronics or Ascent Capital Group. Moreover, it does not provide any home security services to Monitronics International’s customers.

Earlier this month, Ascent Capital Group reported results for the three and six months ended June 30, 2019. Ascent’s Net Revenue for the three and six months ended June 30, 2019 totaled $128.1 million and $257.7 million, respectively.

Ascent’s Net Income for the three and six months ended June 30, 2019 totaled $628.9 million and $601.1 million, respectively.

Monitronics’ Net Loss for the three and six months ended June 30, 2019 totaled $54.2 million and $86.0 million, respectively.

In addition, this month, Monitronics International, Inc. announced that the United States Bankruptcy Court for the Southern District of Texas confirmed the joint partial prepackaged plan of reorganization of Monitronics and certain of its domestic subsidiaries. This confirmation clears the way for Monitronics International to emerge from Chapter 11 protection in early September, if not earlier, with considerably less debt and access to new sources of capital that will support ongoing growth and innovation.

Yesterday, Ascent Capital Group announced that Ascent stockholders approved the proposal to adopt the Agreement and Plan of Merger, by and between Ascent and Monitronics International, dated May 24, 2019, that was considered at the special meeting of Ascent stockholders held on August 21, 2019. Therefore, Ascent Capital Group will merge with and into Monitronics substantially concurrently with the restructuring of Monitronics. Following the stockholders’ approval of the merger proposal, the expectation is that the Merger will be completed on or about August 30, 2019, subject to the satisfaction of additional customary closing conditions.

Ascent Capital Group, Inc. (ASCMB), closed Thursday's trading session at $2.05, up 105%, on 1,450 volume with 6 trades. The average volume for the last 3 months is 70 and the stock's 52-week low/high is $0.200000002/$3.00.

chart

Sabina Gold & Silver Corp. (SGSVF)

Streetwise Reports, The Prospector News, Northern Miner, GlobeNewswire, MingNewsFeed.com, 24Hgold, Market Screener, Resource World, Wallet Investor, TradingView, Stockhouse, Dividend Investor, and Junior Mining Network reported earlier on Sabina Gold & Silver Corp. (SGSVF), and today we report on the Company, here at the QualityStocks Daily Newsletter.

OTCQX-listed, Sabina Gold & Silver Corp. is an emerging precious metals company. It has district scale, advanced, high grade gold assets in one of the world’s newest, politically stable mining jurisdictions - Nunavut, Canada. The Company has its 100 percent owned Back River Gold Project. In addition, Sabina owns a significant silver royalty on Glencore’s Hackett River Project. Sabina Gold & Silver has its head office in Vancouver, British Columbia.

The Company released a Feasibility Study (FS) on its Back River Gold Project. The FS presents a project designed on a fit-for purpose basis, with the potential to produce approximately 200,000 ounces a year for approximately 11 years with a quick payback of 2.9 years.

On December 19, 2017, the Project received its final Project Certificate. The Project received its Type A Water License on November 14, 2018. The Project is now in receipt of all major authorizations for construction and operations. Moreover, the silver royalty on Hackett River’s silver production consists of 22.5 percent of the first 190 million ounces produced and 12.5 percent of all silver produced afterwards.

Earlier this month, Sabina Gold & Silver announced the final results from the remaining four drill holes from 2019’s spring drilling program at its Back River Gold Project in Nunavut. Three drill holes targeted the emerging Nuvuyak gold zone. The fourth drill hole targeted a section of the Hook gold structure, just west of the Goose Main deposit.

Results from drill hole 19GSE566W2, a wedge hole off earlier announced hole 19GSE56 (July 18, 2019), continue to return numerous high grade values over significant widths within a broadly mineralized envelope of iron formation at Nuvuyak. Significant values, within a +150 m section of alteration and mineralization include 10.15 g/t Au over 6.95m, 14.70 g/t Au over 9.25m, and 10.52 g/t Au over 8.60m.

An additional two drill holes, 19GSE564 and 19GSE568, were completed at the Nuvuyak target in a down plunge section of the gold structure. The drilling is situated 320 m down plunge from wedge hole 19GSE566W2 giving the Nuvuyak gold zone a tested strike length of 370 m.

During Q2 2019, Sabina Gold & Silver completed drilling of 6,468 meters over 8 holes at three target areas at the Goose property to follow up on the successes from 2018. Drilling at the recent Nuvuyak discovery was centered on continued scoping of size and grade continuity. It was successful in identifying broad zones of gold mineralization roughly 50 meters up-plunge of the original discovery area.

Sabina Gold & Silver Corp. (SGSVF), closed Thursday's trading session at $1.43, up 11.0988%, on 1,444,615 volume with 956 trades. The average volume for the last 3 months is 110,317 and the stock's 52-week low/high is $0.730000019/$1.50.

chart

Predictive Technology Group, Inc. (PRED)

NetworkNewsWire, Wallmine, Infront Analytics, Zacks, InvestorsHub, Simply Wall St, Insider Financial, Wallet Investor, Stockhouse, The Street, StreetWise Reports, and Dividend Investor reported beforehand on Predictive Technology Group, Inc. (PRED), and we also report on the Company, here at the QualityStocks Daily Newsletter.

Predictive Technology Group, Inc. is a therapeutics and life sciences company listed on the OTC Markets. It is a leader in the use of data analytics for disease identification and subsequent therapeutic intervention via innovative novel gene-based diagnostics, biotechnology treatments and companion therapeutics. The Company previously went by the name Global Enterprises Group, Inc. It changed its corporate name to Predictive Technology Group, Inc. in July of 2015. Predictive Technology Group is based in Salt Lake City, Utah.

The Company’s wholly-owned subsidiaries are Predictive Therapeutics and Predictive Biotech. Through these, it concentrates on four primary clinical categories. These are Endometriosis, Scoliosis, Degenerative Disc Disease and Regenerative Human Cell and Tissue Products.

Predictive Laboratories focuses on clinical and discovery work for human infertility and genetic conditions affecting women and children. Testing is performed using state-of-the-art instrumentation at its CAP and CLIA accredited facility.

Further to Predictive Biotech’s efforts to advance regenerative medicine, Predictive Therapeutics’ commitment is to assisting women in overcoming the devastating consequences of endometriosis through appropriate early-stage diagnosis and subsequent treatment. Subsidiary Predictive Biotech is a leader in human cell and tissue products for use in regenerative medicine. A growing national network of clinics, health systems, researchers and physicians leverage Predictive Biotech’s four primary placental-derived and Wharton’s jelly umbilical cord-derived products (AmnioCyte™, AmnioCyte Plus™, PolyCyte™, CoreCyte™).

Earlier in August, Predictive Technology Group announced that its wholly-owned subsidiary, Predictive Laboratories, commercially launched PGxPLUS+. This is a pharmacogenomic test panel being marketed to pain clinics for patients with chronic pain. PGxPLUS+ assesses genetic factors that play a major role in an individual’s response to medications. Furthermore, Predictive Laboratories has reached a milestone of enrolling 350 patients with chronic pain into an Investigational Review Board-approved clinical study targeted at providing additional insight into the mechanisms of chronic pain and responses to pain therapies.

Yesterday, Predictive Technology Group announced that Predictive Laboratories™ has collected more than 2,500 DNA samples along with comprehensive medical records since acquiring its CLIA operations in March of 2019. Predictive is widening its research initiatives through acquiring new sample collections in chronic pain, pregnancy complications, autism, and female and male infertility.

Mr. Bradley Robinson, Predictive Technology Group’s Chief Executive Officer, said, “The ability to discover specific genetic markers related to the diagnosis, prognosis, and therapeutic response for disease targets can help Predictive find solutions that could transform medical care. A crucial requirement for personalized medicine is the availability of an extensive collection of both human diseased and healthy samples with well-documented medical records.”

Predictive Technology Group, Inc. (PRED), closed Thursday's trading session at $2.24, off by 1.3216%, on 162,399 volume with 184 trades. The average volume for the last 3 months is 684,924 and the stock's 52-week low/high is $0.76999998/$6.90999984.

chart

Abacus Health Products, Inc. (ABAHF)

InvestorX, Market Wire News, Dividend Investor, PR Newswire, Market Screener, New Cannabis Ventures, BioSpace, Stockwatch, Seeking Alpha, TradingView, Stockhouse and Investing.com reported earlier on Abacus Health Products, Inc. (ABAHF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Abacus Health Products, Inc. engages in the development and commercialization of over-the-counter (OTC) registered topical medications with active pharmaceutical ingredients and that contain organic and natural ingredients. This includes a cannabinoid-rich hemp extract containing CBD (cannabidiol) from the Cannabis sativa L plant. Abacus Health Products, Inc. is a subsidiary of Aidance Skincare & Topical Solutions, LLC. Abacus Health Products’ shares trade on the OTC Markets Group’s OTCQX.

Abacus Health Products established in 2014 with the mission to use advanced topical formulations that combine CBD hemp extract (Cannabis sativa L.) with leading topical analgesics (menthol and camphor) to deliver temporary pain relief products to millions of people globally. In 2016, the Company commenced distribution to healthcare practitioners under the CBD CLINIC brand name. Because of premier effectiveness, CBD CLINIC products rapidly became the #1 preferred external analgesics for thousands of practitioners throughout the U.S. In Q3 of 2018, Abacus launched CBDMEDIC directly to the active fitness and mass retail markets.

Of note is that Abacus Health Products is the first global company to develop, brand, and sell OTC topical medications blended with authorized pharmaceutical active ingredients and legal hemp extract. The Company’s CBD CLINIC is sold exclusively to licensed health practitioners. CBDMEDIC is sold directly to consumers by way of retail pharmacies, fitness centers, as well as numerous e-commerce platforms.

The Company’s proprietary formulations are applied topically to treat the pain at the source of the problem. This is in comparison to oral medications that are absorbed by the entire body and may have serious side effects. Abacus designed its formulations to combine a proprietary blend of natural emollients that facilitate deep and quick absorption of pain-relieving analgesic compounds, and powerful, naturally derived terpenes (aromatic oils and analgesic compounds) to temporarily lessen pain.

Last week, Abacus Health Products announced the addition of Matrix Distributors, Inc. as a distributor of Abacus’ CBDMEDIC™ products. In addition, Abacus announced the expansion of retail stores carrying its products with both new and existing retail partners. Matrix Distributors will first roll out 9 CBDMEDIC™ products, including 6 innovative pain relief SKUs (Stock Keeping Units), Acne Treatment Cream and Cleanser, and Eczema Treatment, to up to 250 locations across New York, New Jersey and Pennsylvania during 2019. Further roll-outs are planned for 2020.

Furthermore, Abacus Health Products announced the expanded distribution of about 225 stores in the Midwest and California. A new retail chain partner, with more than 200 locations in California, will roll out to 125 stores during this year. An existing retail partner will roll out to an additional 100 stores across the Midwest.

Abacus will release its 2019 Q2 financial results sooner than previously announced. It will release the results on Tuesday, August 27, 2019, before market open. Management will host a conference call the same day, at 1:00 PM Eastern Time to review the financial results.

Abacus Health Products, Inc. (ABAHF), closed Thursday's trading session at $5.95, up 12.6188%, on 440 volume with 3 trades. The average volume for the last 3 months is 2,158 and the stock's 52-week low/high is $5.21000003/$14.00.

chart

ImageWare Systems, Inc. (IWSY)

TipRanks, Zacks, Super Stock Screener, Street Insider, Wallet Investor, Marketbeat, Simply Wall St, InvestorsHub, Wallmine, 4-Traders, Stockopedia, Insider Financial, and Market Screener reported earlier on ImageWare Systems, Inc. (IWSY), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

ImageWare Systems, Inc. is a leader in mobile and cloud-based, multi-modal biometric identity management solutions. It provides two-factor, biometric and multi-factor cloud-based authentication solutions for the enterprise. The Company serves healthcare, banking, retail/e-commerce, government, as well as law enforcement and public safety markets. ImageWare Systems has its corporate office in San Diego, California. The Company also has offices in Oregon, Canada, Mexico, and Japan.

ImageWare Systems delivers next-generation biometrics as an interactive and scalable cloud-based solution. It brings together cloud and mobile technology to offer two-factor, biometric, and multi-factor authentication for smartphone users, for the enterprise, and across industries. ImageWare’s products support multi-modal biometric authentication. This includes, but is not limited to, face, voice, fingerprint, iris, palm, and more.

All of the biometrics can be combined with or used as replacements for authentication and access control tools (including tokens, digital certificates, passwords, and PINS) to provide the supreme level of assurance, accountability, and user-friendliness for corporate networks, web applications, mobile devices, and PC (Personal Computer) desktop environments.

ImageWare Systems has introduced the ImageWare Digital Identity Platform ™. This is an end-to-end digital biometric identity proofing, authentication and lifecycle management solution. This platform provides the broadest set of identity validation and biometric authentication capabilities in the industry.

At the end of July, ImageWare® Systems announced the integration of the Biointellic™ Intelligent Anti-spoofing System into its existing Digital Identity Platform. This enhancement enables businesses to further increase the security of their systems without increasing friction. Business benefits include mitigating the risk of expensive identity fraud and data breaches, without impacting user adoption and abandonment rates.

Biointellic is a zero-friction, anti-spoofing system. It is used on standard smartphones. The frictionless solution is incorporated into ImageWare Systems’ existing facial recognition capabilities. The anti-spoofing detection is performed on the server, decreasing the chance of data breaches and unauthorized user access caused by spoofing.

ImageWare Systems, Inc. (IWSY), closed Thursday's trading session at $0.555, off by 2.6316%, on 115,100 volume with 41 trades. The average volume for the last 3 months is 75,476 and the stock's 52-week low/high is $0.479999989/$1.79999995.

chart

Processa Pharmaceuticals, Inc. (PCSA)

Zacks, Street Insider, Finance Recorder, BioSpace, Last10k, Financial Buzz, OTC Markets, PR Newswire, Infront Analytics, Stockwatch, Simply Wall St, TradingView, Stockopedia, Stockhouse, TMXmoney, GlobeNewswire and Market Screener reported on Processa Pharmaceuticals, Inc. (PCSA), and we highlight the Company as well, here at the QualityStocks Daily Newsletter.

A clinical stage biopharmaceutical company, Processa Pharmaceuticals, Inc. is developing products to improve the survival and/or quality of life for patients who have a high unmet medical need condition. It has assembled a proven regulatory science development team, management team, as well as Board of Directors. The Processa team has been involved with over 30 drug approvals by the FDA (Food and Drug Administration), including drug products targeted to orphan disease conditions, and 100 FDA meetings. OTCQB-listed, and founded in 2017, Processa Pharmaceuticals is headquartered in Hanover, Maryland.

PCS-499 represents the first Processa Pharmaceuticals drug that can potentially be used in a number of unmet medical need conditions. The Processa process is to develop drugs that are ready for clinical development or have minimal pre-IND enabling studies to complete.

The Company acquires drugs that already have some clinical data to support the targeted treatment. This is whether it be the drug itself, an analog of the drug, or a drug with like pharmacological targets. In addition, Processa navigates through the FDA collaborating with the reviewers to define a complete development program. It develops each drug over 2-4 years, out-licensing the drug either just before pivotal study after Phase 2b or just after the completion of the pivotal study.

Lead product PCS499 will be investigated for the treatment of Necrobiosis Lipoidica. This is a necrotizing skin condition caused by a number of pathophysiological changes. A second unmet medical need under investigation is the use of PCS499 to treat radiation-related adverse effects in head & neck cancer. For both indications there are no FDA approved treatments. In addition, the present standard of care is not adequate for patients.

Recently, Processa Pharmaceuticals provided an update for its continuing Phase 2 Necrobiosis Lipoidica (NL) clinical trial for PCS-499 (PCS499-NL01), a deuterated analog of one of the major metabolites of pentoxifylline (Trental®). The Company’s Phase 2 trial is approaching six months from the announcement of the first patient dosed. The primary goal of the trial is to evaluate the safety and tolerability of PCS-499 in patients with NL. Additionally, the expectation is that safety and efficacy data collected from the trial will provide information for the design of future clinical trials.

Based on toxicology studies and healthy human volunteer studies, Processa Pharmaceuticals and the FDA agreed that a PCS-499 dose of 1.8 grams/day would be the highest dose administered to NL patients in this Phase 2 trial. As anticipated, the PCS-499 dose of 1.8 grams/day, 50 percent greater than the maximum tolerated dose of pentoxifylline, appears to be well tolerated with no serious adverse events reported.

Processa Pharmaceuticals, Inc. (PCSA), closed Thursday's trading session at $2.43, even for the day, on 2,112 volume with 2 trades. The average volume for the last 3 months is 420 and the stock's 52-week low/high is $1.50/$4.40000009.

chart

CurAegis Technologies, Inc. (CRGS)

Penny Stock Tweets, Dividend Investor, Insider Mole, Equity Clock, Market Screener, Morningstar, MarketWatch, 4-Traders, InvestorsHub, Stockwatch, Investor Place, Simply Wall St, Marketbeat, Capital Cube, YCharts, Stock Invest, Barchart, The Street, OTC Markets, Infront Analytics, Stockhouse, last10k, Wallet Investor, and TradingView reported earlier on CurAegis Technologies, Inc. (CRGS), and today we choose to report on the Company, here at the QualityStocks Daily Newsletter. 

Technologies, Inc. develops and markets advanced technologies in the areas of power, safety, and wellness. The Company consists of two independent divisions. One is its CURA Division and the other is its Aegis Division.  CurAegis is now concentrating on commercialization strategies in diverse technologies. These include the CURA system, which includes the myCadian™ watch that measures degradation of alertness and sleep attributes; the Z-Coach e-learning education and training tool, and the Aegis hydraulic pump. OTCQB-listed, CurAegis Technologies is based in Rochester, New York.
  
The CURA™ system and the myCadian™ watch enable the user and third parties to anticipate and prevent undesired or disastrous situations caused by the degradation of alertness. CurAegis completed its validation studies of the CURA System at the University of Colorado at Boulder and the University of Rochester Medical Center. The Company previously said that it can now state that it can predict a person’s fatigue level, at close to laboratory accuracy, in real-time.

The CURA System consists of hardware and software, which measures numerous metrics to establish that a person's ability to perform a task or job appears to be degrading. The CURA division is developing a proprietary technology and family of products designed to measure the reduction in a person’s alertness and to train persons on how to improve alertness levels. The CURA System gives a person accurate and relevant real-time information regarding their current and long-term sleep and fatigue health.

The Company’s Aegis hydraulic pump (Aegis Division) is an innovative hydraulic design. Its goal is to deliver better efficiencies in a package that is smaller and lighter than contemporary technologies.  Moreover, in 2015, the Z-Coach e-learning tool was acquired by CurAegis Technologies. The Z-Coach® Wellness Program is a robust, proven and proprietary online sleep training and education solution to address sleep issues and improve wellness.

Recently, Mr. Richard A. Kaplan, Chief Executive Officer of CurAegis Technologies announced that Mr. Lance F. Drummond was appointed to the Company’s Board of Directors. At present, Mr. Drummond is a Board member of Federal Home Loan Mortgage Corporation (Freddie Mac). He has served on the Audit Committee and Nominations and Governance Committee since 2015.  He is a Board member for United Community Bank, Inc. since 2018, where he serves on the Risk Committee, Nominating and Governance Committee and Compensation Committee.

CurAegis Technologies, Inc. (CRGS), closed Thursday's trading session at $0.105, up 31.25%, on 25,000 volume with 4 trades. The average volume for the last 3 months is 13,632 and the stock's 52-week low/high is $0.050500001/$0.490000009.

chart

Petrolia Energy Corp. (BBLS)

Insider Monitor, MarketWatch, Stockhouse, InvestorsHub, Infront Analytics, Capital Cube, Stockflare, OTC Markets, 4-Traders, Simply Wall St, GuruFocus, TradingView, and Market Exclusive reported previously on Petrolia Energy Corp. (BBLS), and today we report on the Company, here at the QualityStocks Daily Newsletter.

Petrolia Energy Corp.’s main concentration is employing inventive technology and the implementation of its own cutting-edge, proprietary technologies to improve the recoverability of existing oil fields. Its team of experts has a first-rate record of converting oil fields into compliant, producing, and profitable entities. Petrolia Energy’s primary goals are to locate undervalued assets, identify properties with resolvable environmental and mechanical issues, and lessen lift costs resulting in increased shareholder value. OTCQB-listed, Petrolia Energy is based in Houston, Texas.

The Company focuses on new oil wells in established areas of oil production. Petrolia has more than eight decades of operational and management experience throughout the energy industry. It announced in October 2016 that it purchased a 90 percent working interest (WI) via a purchase and sale agreement (PSA) and a share exchange agreement (SEA) with Jovian Petroleum Corp. and its subsidiaries, Jovian Resources, LLC and SUDS Properties, LLC,  increasing its ownership to 100 percent  WI for the Slick Unit Dutcher Sands (SUDS) field in Creek County, Oklahoma. 

Petrolia Energy completed in 2017 the acquisition of a 60 percent net WI in the Twin Lakes San Andres Unit (TLSAU) lease, in Chaves County, New Mexico. This brings its total ownership of TLSAU to 100 percent. Overall, the TLSAU lease includes 4,864 gross and net acres; 2,292,903 barrels of 1P reserves; 44 existing vertical oil production wells, 12 that are now producing; 44 existing injection wells for water flood and/or CO2 injection for enhanced oil recovery (EOR); broad surface infrastructure, and a dedicated Caprock well to supply future water flood operations.

Petrolia Energy has signed the Slick Unit Exploration and Development Agreement with Boone Operating, Inc. to explore and develop the Misener and Simpson Formations at the Slick Unit Dutcher Sands Field (SUDS Field). Boone Operating is a private Exploration & Production company. 

Petrolia Energy has also acquired a 25 percent Working Interest (WI) in the Luseland, Hearts Hill, and Cuthbert fields in southwest Saskatchewan and eastern Alberta. This acquisition consists of WIs in 64 sections (about 41,526 acres) with 240 oil and 12 natural gas wells producing on the properties.  Additionally, there are several idle wells with potential for reactivation and 34 sections of undeveloped land (about 21,760 acres).

Petrolia Energy has centered its acquisition efforts in core regions in Texas, New Mexico and Oklahoma. The Company is also pursuing its strategy to offer low-cost operational solutions in established plays, including the Minerva-Rockdale shallow oil play in Texas, the Dutcher Sands play in Oklahoma and its San Andres play in New Mexico.

Petrolia Energy Corp. (BBLS), closed Thursday's trading session at $0.078, up 32.2034%, on 5,000 volume with 1 trade. The average volume for the last 3 months is 7,368 and the stock's 52-week low/high is $0.0401/$0.214949995.

chart

U.S. Stem Cell, Inc. (USRM)

InvestorsHub, MarketWatch, TradingView, and Money Morning reported on U.S. Stem Cell, Inc. (USRM), and today we report on the Company, here at the QualityStocks Daily Newsletter.

U.S. Stem Cell, Inc. is a developing business in the regenerative medicine/cellular therapy industry. The Company is a developer of novel autologous cell therapies, and a provider of physician-based stem cell therapies to human and animal patients. U.S. Stem Cell is based in Sunrise, Florida. The Company formerly went by the name Bioheart, Inc. It changed its name to U.S. Stem Cell, Inc. in October of 2015.

The Company has three operating divisions: US Stem Cell Training, Vetbiologics, and US Stem Cell Clinic. U.S. Stem Cell is a leader in the development of proprietary, physician-based stem cell therapies and novel regenerative medicine solutions. Its concentration is on the discovery, development, and commercialization of cell-based therapeutics that prevent, treat, or cure disease through repairing and replacing damaged or aged tissue, cells and organs and restoring their normal function.

U.S. Stem Cell’s business includes the development of proprietary cell therapy products and revenue generating physician and patient based regenerative medicine/cell therapy training services. In addition, the Company’s business includes cell collection and cell storage services, the sale of cell collection and treatment kits for humans and animals, and the operation of a cell therapy clinic. 

U.S. Stem Cell’s lead product candidate is MyoCell®. This is a muscle stem cell therapy intended to improve cardiac function months or even years after a patient has suffered severe heart damage due to a heart attack.

MyoCell SDF-1 has received approval from the Food and Drug Administration (FDA) to commence human clinical trials. The intention of MyoCell SDF-1 is to be an improvement to MyoCell.

U.S. Stem Cell has developed a strategic alliance with Advanced Stem Cell Rx (ASC). This includes the development of autologous stem cell treatment centers across the United States. ASC is a U.S. based provider of regenerative medicine programs.

U.S. Stem Cell announced in January 2018 that it reached an important milestone of 10,000 kit sales of its proprietary Adipocell™ product. This is a direct result of its relationships with 287 clinics in the United States and 700-plus physicians worldwide offering the Company’s proprietary stem cell products and services.

Recently, U.S. Stem Cell announced Renewing Our Heroes - a charitable health initiative created to provide first responders and other civil service personnel with access to alternative medical care they would otherwise be unable to obtain - will now offer the Company’s stem cell procedures and protocols to its recipients following injuries and conditions that occur in the line of duty.

Mr. Mike Tomas, U.S. Stem Cell’s President and Chief Executive Officer, said, "Expansion of our stem cell protocol into the line of service for our first responders means we are starting to reach more and more Americans who otherwise would never have access to this incredible regenerative therapy. It is an honor for our organization to know the true heroes of our country can now have access to this standard of care."

U.S. Stem Cell, Inc. (USRM), closed Thursday's trading session at $0.0065, up 30.00%, on 1,556,332 volume with 41 trades. The average volume for the last 3 months is 1,440,888 and the stock's 52-week low/high is $0.0037/$0.039999999.

chart

Boston Therapeutics, Inc. (BTHE)

MissionIR,  Tiny Gems, SmallCapVoice, PennyStocks24,   FeedBlitz, Wall Street Mover,  RedChip, TaglichBrothers,  Stock News Now, TopPennyStockMovers, and Information Solutions Group  reported  earlier  on Boston Therapeutics, Inc. (BTHE), and today we are reporting on  the Company, here at the QualityStocks Daily Newsletter. 

Boston Therapeutics, Inc. is a developer of complex carbohydrate therapeutics to treat diabetes and inflammatory diseases. The Company’s product pipeline  centers  on developing and commercializing therapeutic molecules  that  address diabetes and inflammatory diseases. OTCQB-listed,  Boston Therapeutics is based in Lawrence, Massachusetts.

The Company’s  product pipeline includes BTI-320. This is a  non-systemic, non-toxic,  chewable complex carbohydrate-based compound. The design of it is to lessen post-meal glucose elevation. BTI-320 is a proprietary polysaccharide. 

BTI-320 works in the gastrointestinal tract to block the action of carbohydrate-hydrolyzing enzymes, which break down complex carbohydrates into simple sugars, reducing  the availability of glucose for absorption into the bloodstream. 

Boston Therapeutics  entered a  clinical trial agreement with Joslin Diabetes Center to be the lead clinic  in a Phase II study of BTI-320. In addition,  the Company’s  product pipeline  includes IPOXYN™. This is an injectable anti-necrosis drug. The design of it at first is to treat lower limb ischemia associated with diabetes.  

Boston Therapeutics’  product pipeline also  includes OXYFEX™. This product can serve as the only available oxygen delivery mechanism for animals suffering ischemia or traumatic and surgical blood loss events. OXYFEX™ is  the Company’s  veterinary facsimile to IPOXYN™.

Furthermore, Boston Therapeutics  developed and markets SUGARDOWN®. This is a non-systemic,  complex carbohydrate-based dietary food supplement. The design of SUGARDOWN® is to support healthy blood glucose.

SUGARDOWN®, in its present formulation, is a natural sugar blocker dietary supplement product made completely from a non-digestible sugar molecule, which can help people maintain healthier weight levels. It is the first chewable tablet of its kind. 

In 2015, Boston Therapeutics announced that its affiliate, Advance Pharmaceutical Company Limited (APC), began the  SUGARDOWN®  clinical trial in Hong Kong. Advance is evaluating the effect of  SUGARDOWN®  on Post-Prandial Hyperglycemia in Chinese subjects with Pre-Diabetes.  The lead clinical site is the Department of Medicine, The Chinese University of Hong Kong  (CUHK), Prince of Wales Hospital. 

In April 2017, Boston Therapeutics and  Advance Pharmaceutical announced  the fully funded new trial plans to support the safety and efficacy of BTI-320, starting with a randomized, placebo-controlled, double-blinded, multi-center, global study on type 2 diabetic (T2D) patients.

Recently, Boston Therapeutics announced that effective sugar reduction with the investigative BTI-320 formulation necessitates only one tablet. Findings were confirmed by the most recent proof-of-concept study conducted in high-risk Chinese subjects with pre-diabetes. A formulation, in the form of a dietary supplement, is currently available as SUGARDOWN®, SUGARBLOCK and SUGARBALANCE in the Unites States and Asia.

Moreover, in December, Boston Therapeutics announced that it expanded its partnership with Advance Pharmaceutical Company Limited (APC) to distribute in Korea. Following the extension of the licensing and distribution agreement with APC, a registered formulation, marketed as a food supplement under the name SUGARBALANCE is now available in Korea.  This significant shipment marks a start to the sales of SUGARBALANCE in the territory.

Boston Therapeutics, Inc. (BTHE), closed Thursday's trading session at $0.02, up 25.7862%, on 1,453,574 volume with 106 trades. The average volume for the last 3 months is 36,175 and the stock's 52-week low/high is $0.0091/$0.062399998.

chart

Dais Analytic Corp. (DLYT)

HotOTC, SmallCapVoice, CoolPennyStocks, MadPennyStocks, StockEgg, StockRich, Stockpalooza, Money Morning, Penny Stock Rumble, FeedBlitz, M2 Communications, SmallCap Pulse, BullRally,  PennyInvest, PennyStockVille, and Greenbackers  reported  earlier on Dais Analytic Corp. (DLYT), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Dais Analytic Corp sells its industry-changing nanomaterial technology into the global water, air, and energy markets. A commercial nanotechnology materials enterprise, the Company provides nanotechnology-based applications for heating & cooling, water treatment, and energy storage. It is commercializing its unique Aqualyte™ family of nano-structured materials and processes centering on disruptive air, energy, and water applications. Dais Analytic is headquartered in Odessa, Florida.  

The uses of the Aqualyte™ family of nano-structured materials and processes include ConsERV™. This is a commercially available engineered energy recovery ventilator (a heating, ventilation, and air conditioning (HVAC) product). 

In addition, the uses include NanoAir™. This is an early beta-stage water-based, no fluorocarbon producing refrigerant cooling cycle.  Uses also include NanoClear™. This is an early beta-stage method for treating contaminated water to provide 1,000 times cleaner potable water.

The NanoClear™ process has consistently shown that Dais Analytic’s novel Aqualyte® material can separate most contaminants from water, realizing almost 'parts per billion' clean product water with little or no fouling of the vital membrane component. 

NanoClear™ is a leading-edege water cleaning architecture enabled by the features in the Company’s nanomaterial - Aqualyte™. The NanoClear™ product line is a critical application in purifying contaminated water having high salt content, low pH, or where the requirement for Total Dissolved Solid (TDS) in the product water is 10 or less. 

Furthermore uses include NanoCAP™. Dais indicates that NanoCAP™ holds promise to use the Aqualyte™ family to form a disruptive, non-chemical, energy-storage device (an ultra-capacitor) when completed for use in transportation, renewable energy, and also 'smart grid' configurations.

Recently, Dais Analytic announced it signed a 7 year, non-exclusive agreement with the Menred Group, Zhejiang province, China, to provide its Aqualyte moisture transfer nanomaterial for use in a newer line of Menred energy recovery ventilators (ERV) to sell into the increasing Chinese heating, ventilation and air conditioning (HVAC) market.

Energy Recovery Ventilators are used in association with HVAC equipment to save capital and operating costs. This is while improving the quality of life for the building's occupants.

High effectiveness ERVs, such as ConsERV™ or Menred Group's new line of ERVs to be built utilizing Dais Analytic's Aqualyte nanomaterial, enable architects and engineers to design buildings with considerable volumes of filtered, preconditioned supply air.

Mr. Brian Johnson Dais Analytic’s Chief Technology Officer, said in July 2017, "Dais' ConsERV™ has long been a leader in this field as established by our Air-Conditioning, Heating and Refrigeration Institute (AHRI) certified performance -- along with other similar ratings from 3rd party rating company's worldwide. Our Aqualyte™ nanomaterial, now in its 4th generation, drives this performance and we are excited about working with Menred to bring a new series of ERVs with Aqualyte to the growing Chinese ERV market."

Dais Analytic Corp. (DLYT), closed Thursday's trading session at $0.004, up 154.7771%, on 123,113,797 volume with 886 trades. The average volume for the last 3 months is 8,695,109 and the stock's 52-week low/high is $0.000699999/$0.054999999.

chart

Continental Energy Corp. (CPPXF)

TopPennyStockMovers, Streetwise Reports, and Agoracom reported previously on Continental Energy Corp. (CPPXF), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Continental Energy Corp. is an emerging developer of conventional and alternative energy capacity integrated with upstream and downstream petroleum supply within the Republic of Indonesia. Listed on the OTC Markets, the Company’s commitment is to developing hybrid renewable electrical power generation capacity and profitably operating mini-grid distribution networks in the huge, under-served markets of the fast-growing economies encircling the Indian Ocean Rim.

Established in 1984, Continental Energy is headquartered in Vancouver, British Columbia. The Company previously went by the name Continental Copper Corp. It changed its corporate name to Continental Energy Corp. in October of 1997.

The Company’s core competency exists in Indonesia. It has 30 years of experience in Indonesia. This has given Continental Energy the business relationships and local operating experience necessary to capitalize on the rising energy demand in this country.

In addition, Continental Energy has its business combination with the Ruaha River Power Company. This business combination provided instant entry into Tanzania. This is where the best-in-Africa commercial incentives for small scale renewable energy developers are in place to foster new supply of power to off-grid communities.

Recently, Continental Energy announced the filing on SEDAR of its audited consolidated financial statements and its management discussion and analysis for its Fiscal 2017 year ended June 30, 2017. Continental had a Loss from Operations of $439,606 during Fiscal 2017 versus a Loss from Operations of $473,289 during Fiscal 2016. This represents a decrease of $33,683, mainly because of lower professional fees and share-based payments.

The Company had a loss per share of $0.00 in both 2017 and 2016. Continental’s administrative costs were lower by $14,428 in 2017 versus 2016. This was chiefly because of reduced professional fees: 2017 - $376,842; and 2016 - $391,270. As at the end of this Fiscal Year 2017, Continental Energy’s Working Capital deficit was $1,721,256 versus a Working Capital deficit of $1,282,380 at the end of Fiscal 2016.

Continental Energy Corp. (CPPXF), closed Thursday's trading session at $0.019, up 35.7143%, on 2,000 volume with 1 trade. The average volume for the last 3 months is 16,381 and the stock's 52-week low/high is $0.008/$0.048999998.

chart

Lixte Biotechnology Holdings, Inc. (LIXT)

Small Cap Network, Street Insider, Wallet Investor, Stockopedia, Dividend Investor, PR Newswire, 4-Traders, YCharts, OTC Markets, Simply Wall St, Last10k, Market Screener, InvestorsHub, MarketBeat, Stockhouse, and Morningstar reported previously on Lixte Biotechnology Holdings, Inc. (LIXT), and today we are highlighting the Company, here at the QualityStocks Daily Newsletter.

Lixte Biotechnology Holdings, Inc. operates as a drug discovery company. It uses biomarker technology to identify enzyme targets related with serious common diseases and designs novel compounds to attack those targets. A clinical-stage pharmaceutical company, its product pipeline is chiefly centered on inhibitors of protein phosphatases, used alone and in combination with cytotoxic agents and/or X-ray and immune checkpoint blockers. OTCQB-listed, Lixte Biotechnology Holdings is based in East Setauket, New York.

The Company has identified molecular signaling pathways altered in disease states and designed compounds that can safely target them in animal models. Its current drug portfolio includes inhibitors of serine/threonine protein phosphatases vital to cell division and DNA damage repair and inhibitors of protein deacetylases, which regulate pathways of gene expression and protein degradation. The phosphatase inhibitors enhance the effectiveness of cytotoxic anti-cancer drugs in general and radiation therapy. This makes them potentially useful for the treatment of manifold cancers in combination with existing standard chemotherapy regimens and with the developing targeted cytotoxic therapies of personalized cancer medicine.

In addition, in a pre-clinical study done with scientists under collaborative research and development agreements at the National Institutes of Health, Lixte Biotechnology’s lead compound, LB-100, enhanced the antitumor activity of a major immune checkpoint inhibitor. As a result, this raises the possibility that in addition to improving the efficacy of standard cytotoxic anti-cancer drugs, the Company’s phosphatase inhibitors may potentiate immunotherapy regimens (Ho 2017).

Recently, Lixte Biotechnology announced that the first patient was enrolled in its Phase 1b/2 study of the safety and therapeutic benefit of the Company’s lead clinical compound, LB-100, in patients with low and intermediate-1 risk myelodysplastic syndrome (MDS) who have failed or are intolerant of standard treatment (NCT03886662).

Dr. John S. Kovach, Founder and Chief Executive Officer of Lixte Biotechnology, said, “Because there are no standard treatments for patients with refractory MDS, from a statistical standpoint as few as 7 objective responses among the first 47 patients would be considered encouraging and justify proceeding to a Phase 3 trial. Of course, we hope that in the current trial LB-100 will be associated with even higher rates of objective benefit to these patients allowing us to move to Phase 3 before reaching 47 entries.”

Lixte Biotechnology Holdings, Inc. (LIXT), closed Thursday's trading session at $1.3301, up 20.9182%, on 7,337 volume with 14 trades. The average volume for the last 3 months is 1,947 and the stock's 52-week low/high is $0.275000005/$1.45000004.

chart

The QualityStocks Company Corner

Pressure BioSciences Inc. (PBIO)

The QualityStocks Daily Newsletter would like to spotlight Pressure BioSciences Inc. (PBIO).

Pressure BioSciences, Inc. (OTCQB: PBIO) (“PBI” or the “Company”), a leader in the development and sale of broadly enabling, pressure-based instruments, consumables, and platform technology solutions to the worldwide life sciences industry, today announced it has received two additional purchase orders for its revolutionary BaroShear™ K45 processing system. This novel processing system is based on the Company’s proprietary Ultra Shear Technology™ (UST™) platform. The BaroShear K45 is a unique and powerful nanoemulsification system designed to resolve one of the most critical problems facing the CBD industry today: the extremely poor solubility of CBD Oil in water.

Pressure BioSciences Inc. (PBIO) develops, markets and sells proprietary laboratory instrumentation and associated consumables to the life sciences sample preparation market. Sample preparation refers to the wide range of activities that precede most forms of scientific analysis. It is often complex and time-consuming, yet a critical part of scientific research. The market for sample preparation products is currently estimated at $6 billion worldwide.

The Company’s product line can be used to exquisitely control the sample preparation process. It is based on a patented, enabling technology platform called pressure cycling technology (“PCT”). PCT uses alternating cycles of hydrostatic pressure between ambient (14.5 psi) and ultra-high levels (up to 100,000 psi) to safely and reproducibly control critical biological processes, such as the lysis (breakage) of cells, the digestion of proteins, and the inactivation of pathogens.

Pressure BioSciences’ product line is led by its newly released, next-generation Barocycler 2320EXTREME instrument. Named a finalist in the prestigious 2017 R&D Awards (also known as the “Oscars of Innovation”), the Barocycler 2320EXT is already being touted by some key opinion leaders as an essential element of the $1.8 billion U.S. “Cancer Moonshot” program. For example, Professor Phil Robinson, Co-head of the cancer research center of the Children’s Medical Research Institute (Sydney, Australia), said in a recent interview: “We are collecting the whole proteome on 70,000 tumor samples from all classes where complete clinical outcome is known. Due to its unique capabilities, the Barocycler 2320EXT has become a critical part of our program. It is the primary enabler of the high-throughput component of the project. Without this step, our project simply could not be done. In fact, the Barocycler 2320EXT works so well we have just purchased two more.”

Momentum is building when it comes to the potential for using the Company’s unique PCT technology platform. Leading scientists are intrigued by Pressure BioSciences’ approach, which among other attributes, revolutionizes the process of rupturing cells (lysis) for further study, yielding superior biomolecules for investigation. The Company’s technology transcends current methods of breaking open cells, which use chemicals, blades, metal beads, or other damaging and altering methods that can ultimately adversely affect the result for researchers. Pressure BioSciences’ PCT technology utilizes customized, controlled hydrostatic (water) pressure to rupture cells in a chamber, enabling exquisitely customized levels of pressure to optimally break open different types of cells at prescribed pressure levels—something never before accomplished in a commercial setting. Using this pioneering method, the result is a truer, more legitimate sample, which boosts the efficacy of research and the quality of results. The potential impact of this technology on scientific advancement is enormous, enabling research scientists to begin their studies with biological samples of unprecedented integrity, with the potential to improve research outcomes at the earliest, most critical step. PCT can additionally inactivate pathogens (e.g., viruses, bacteria) using hydrostatic pressure, making the samples safer to study—another innovation with astronomical potential for application in a variety of markets.

The Company’s high-pressure instruments for research purposes are marketed throughout the United States, Europe, China and Japan. To date, Pressure BioSciences has installed nearly 300 PCT Systems in over 165 leading academic, government, biotech and pharma laboratories around the world. Its primary applications are in biomarker discovery, forensics, agriculture and pathology. Over 100 scientific papers have been published on the advantages of the PCT platform, which is also being used in the specialized fields of drug discovery and design, bio-therapeutics characterization, soil and plant biology, vaccine development and histology.

Impressive as their biotech business is, there is more to the PBI story. Pressure BioSciences recently received two patents in China for its novel Ultra Shear Technology (UST), a process that has potential in a wide range of industrial applications, including extending the shelf life of some food products and making two insoluble liquids (like oil in water) soluble. Patents have also been filed in many other countries worldwide. UST is a novel technique based on the use of intense shear forces generated from ultra-high-pressure valve discharge.

This important technology has the potential to play a significant role in a number of commercially important areas through its ability to create high-quality, stable nanoemulsions. Scientific studies indicate that improved absorption, higher bioavailability, greater stability, lower surfactant levels and other advantages can be achieved with nanoemulsions – all hugely important factors in the fields of nutraceuticals, cosmetics, pharmaceuticals, and in various medical products. There is an enormous opportunity in the cannabis market, since the technology can potentially reduce oil droplets containing cannabidiol (CBD) to nanoparticles, after which they can be safely suspended in a stable water solution—something many companies have endeavored to achieve without success. Researchers looking for a way to increase the bioavailability of cannabinoids in the body will find this technology a game changer.

The Company’s UST technology also has possibilities in the production of clean label foods, which are currently processed using several innovative methods, including high-pressure treatments (such as Starbucks’ Evolution line of juices). In 2015, the worldwide market for high-pressure processed (HPP) food was estimated at U.S. $10 billion. UST uses ultra-high pressures and certain valves to generate intense shear forces under controlled temperature conditions to produce nanoemulsions, and which also significantly reduces food-borne pathogens. Pressure BioSciences’ initial focus with this technology will be to evaluate UST for the production of high-quality dairy products and beverages.

Pressure BioSciences Inc. (PBIO), closed Thursday's trading session at $2.65, up 38.0208%, on 36,029 volume with 133 trades. The average volume for the last 3 months is 9,784 and the stock's 52-week low/high is $1.25/$4.0999999.

Recent News

chart

Green Growth Brands Inc. (CSE: GGB) (OTCQB: GGBXF)

The QualityStocks Daily Newsletter would like to spotlight Green Growth Brands Inc. (OTCQB: GGBXF).

Green Growth Brands Inc. (CSE: GGB) (OTCQB: GGBXF) announced today the closing of its previously announced "bought deal" short form prospectus offering (the "Offering") of units of the Company ("Units") for aggregate gross proceeds of C$50,225,000.

Green Growth Brands Inc. (CSE: GGB) (OTCQB: GGBXF) is a lifestyle-oriented cannabis and cannabidiol (“CBD”) consumer products company with a portfolio of lifestyle brands customized to connect specific, like-minded customers. Each Green Growth Brand provides the best quality products within a retail experience that appeals to users in an environment that is emotionally branded and easy to navigate.

In the next five years, the cannabis industry will generate more than $28 billion of new revenue from an estimated 14 million new customers, according to Ackrell Capital’s 2018 Cannabis Investment Report. Meanwhile, Hemp Business Journal projects that the CBD market will increase 8x to $3 billion by 2021, up from $200 million in 2017. Green Growth Brand intends to dominate in these markets with a lineup up products grown, manufactured and presented with the highest quality standards in mind.

Products under the Green Growth Brand umbrella include:

  • CAMP: A kiosk-type store where consumers can experience beautifully crafted lifestyle products that enhance one’s journey to self-discovery.
  • Seventh Sense: A CBD-infused body care collection crafted from the finest botanicals and fragrances on earth. Created to maximize the properties and aromatics of each ingredient, Seventh Sense natural products are CBD-infused botanical therapy.
  • Meri+Jayne: Fiercely authentic and wholly unapologetic, Meri+Jayne is a youthful, full-on celebration of what makes each person unique. Expect the unexpected when it comes to this mix of amazing products.
  • Green Lily: A place for women to explore a new world of wellness. With advice on every product, from efficacy to usage, Green Lily guides guests through beautiful new ways to experience cannabis and CBD.
  • The +Source: Located in Las Vegas and Henderson, Nevada, The+Source dispensaries operated by Green Growth Brands serve both medical patients and retail customers. Green Growth Brands also operates a grow and production facility in Post, Nevada, and recently entered into definitive agreements to acquire a Pahrump, Nevada, cultivation facility.
  • XanthicBiopharms is the owner of valuable intellectual property that turns THC(Tetrahydrocannabinol) and CBD into a water-soluble substance. As a result of combining Green Growth Brands and Xanthic, this technology is being used to create incredible new products.

Business Strategy

Green Growth Brands has identified numeroushitches in the current cannabis retail space. The company intends to counter these challenges and provide a customer experience ripe with a friendly staff, in-stock assortments, efficient operations and more. The company’s retail partners provide distribution opportunities within 4,000 stores, as well as robust and established digital platforms to best reach the modern consumer.

Management

Green Growth Brands brings together a collection of expert retailers, scientists, botanists, developers, artists and business leaders for the benefit of building community. Led by an executive management team steeped in decades of experience with several of America’s most successful brands, including Victoria’s Secret, American Eagle Outfitters, Bath & Body Works, Limited Brands and Designer Shoe Warehouse, Green Growth Brands is uniquely positioned to create memorable brands, retail experiences, and quality products for the emerging cannabis industry.

Chief Executive Officer Peter Horvath heads strategy and execution across all company channels, and previously took shoe retailer DSW public on the NYSE at $1.5 billion. As a dynamic, creative brand leader, team builder, and specialty retail veteran with deep roots in finance, Horvath’s unique ability to understand the big picture while never missing the subtle details is a critical factor in Green Growth Brands’ success and brand popularity among customers.

Chief Marketing Officer Scott Razek is a brand strategist, storyteller and strategic marketer. Razek‘s 25 years of experience in brand building, product development and customer experience focus are a key differentiator for the Green Growth Brands portfolio.

CAO Ed Kistner brings 33 years of multifaceted experience at leading retail businesses, notably in finance, merchandise planning, operations and stores. His well-rounded experiences in fast-changing environments position Kistner to be the architect of the operational execution at Green Growth Brands.

CSO Kellie Wurtzman brings significant retail leadership to Green Growth Brands with a proven track record of leading high-performance stores and teams across multiple retail sectors. Her unmatched experience in identifying and supporting developing business opportunities is ideal for evolving the cannabis industry and will be instrumental in expanding operations at Green Growth Brands.

Headquartered in Columbus, Ohio, Green Growth Brands is traded on the Canadian Securities Exchange and on the OTCQB, providing investors with increased access to data, transparency and liquidity.

Green Growth Brands Inc. (OTCQB: GGBXF), closed Thursday's trading session at $1.40254, up 1.9584%, on 212,291 volume with 228 trades. The average volume for the last 3 months is 481,815 and the stock's 52-week low/high is $1.29910004/$5.20499992.

Recent News

chart

Genprex Inc. (NASDAQ: GNPX)

The QualityStocks Daily Newsletter would like to spotlight Genprex Inc. (NASDAQ: GNPX).

Genprex Inc. (NASDAQ:GNPX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), a multifaceted financial news and publishing company for private and public entities. To view the full publication, titled “Record Revenues, Milestone Achievements Indicate Strength, Potential of Biotech Sector,” visit: http://nnw.fm/vn2I8.

Genprex Inc. (NASDAQ: GNPX) is a clinical-stage gene therapy company developing potentially life-changing technologies for cancer patients based upon a unique proprietary technology platform, including Genprex’s initial product candidate, Oncoprex™ immunogene therapy for non-small cell lung cancer (NSCLC). Genprex’s platform technologies are designed to administer cancer-fighting genes by encapsulating them into nanoscale hollow spheres called nanovesicles, which are then administered intravenously and taken up by tumor cells where they express proteins that are missing or found in low quantities.

Research and Development

Genprex holds a portfolio of 30 issued and two pending patents covering its technologies and targeted molecular therapies. The company’s research and development program is focused on identifying and developing leading-edge gene therapies that can be used alone or in combination with other therapies for treatment of cancer.

Genprex’s initial product candidate is Oncoprex™, an immunogene therapy for the treatment of non-small cell lung cancer (NSCLC). Oncoprex works by interrupting cell signaling pathways that cause replication and proliferation of cancer cells, re-establishes pathways for apoptosis (or programmed cell death) in cancer cells, and modulates the immune response against cancer cells. Oncoprex has also been shown to block mechanisms that create drug resistance.

Preclinical research is being conducted with the goal of developing Oncoprex to be administered with targeted therapies in other solid tumors, and with immunotherapies in NSCLC and other solid tumors. In addition, Genprex has conducted and plans to continue research into other tumor suppressor genes associated with chromosome 3p21.3, as well as other potential applications of the company’s immunogene therapy platform.

Clinical Trials

Genprex is currently conducting the second phase of a phase I/II clinical trial at the University of Texas MD Anderson Cancer Center in Houston. The company plans to expand its clinical program by adding a new clinical study evaluating Oncoprex™ in combination with a checkpoint inhibitor for treatment of Stage IV or recurrent NSCLC. In research presented at the 2017 Annual Meeting of the American Association of Cancer Research in Washington, D.C., Genprex’s collaborators showed that TUSC2 in combination with PD-1 checkpoint inhibition has a significantly greater anti-tumor effect in lung cancer than either agent alone. The research also shows that TUSC2 in combination with PD-1 blockade has synergistic activity in upregulating natural killer (NK) cells, correlating with prolonged survival in mice.

TUSC2 (Tumor Suppressor Candidate 2) is a tumor suppressor gene that is absent or deficient in cancer cells of many different cancer types.

The Market

Genprex technologies seek to bridge a critical gap by combining with targeted therapies and immunotherapies to provide treatments to large patient populations who would otherwise not be candidates for those therapies or who have become resistant to them. Genprex technologies are being developed to overcome genomic limitations which are inherent in targeted therapies and immunotherapies in order to provide new treatment solutions to large cancer populations, such as those with lung cancer.

Each year, more people die of lung cancer than of colon, breast and prostate cancers combined. NSCLC is the most common type of lung cancer, accounting for about 85 percent of all lung cancers, according to the American Cancer Society (“ACS”). Despite radical advances in drug development and novel therapeutic standards, survival for late stage lung cancer has not improved significantly in the past 25 years.

Senior Management

Chairman and Chief Executive Officer J. Rodney Varner, JD, is a co-founder of Genprex and has served in these roles since August 2012. He has more than 35 years of legal experience with large and small law firms and as outside general counsel of a Nasdaq-listed company. Varner has served as counsel in company formation, mergers and acquisitions, capital raising, other business transactions, protection of trade secrets and other intellectual property, real estate, and business litigation. He is a member of the State Bar of Texas and has been admitted to practice before the U.S. Court of Appeals for the Fifth Court and the U.S. Tax Court.

Julien L. Pham, M.D., MPH, is president and chief operating officer of Genprex. In March 2013, Dr. Pham co-founded RubiconMD, a healthcare IT company that connects primary care providers to specialists for additional guidance and opinions on medical cases and served as its chief medical officer. He has served on the faculty at Harvard Medical School’s Brigham and Women’s Hospital and is a board-certified internal medicine doctor and nephrologist.

Ryan M. Confer, MS, has served as Genprex chief financial officer since September 2016. Confer has more than 10 years of executive experience in planning, launching, developing, and growing emerging technology companies and has served in the chief operating and chief financial roles for non-profit and for-profit entities since 2008. Confer has also served as an international business development consultant for the University of Texas at Austin’s IC2 Institute, where he focused on evaluating the commercialization potential of nascent technologies in domestic and international markets applicable to technology incubator programs associated with the University. Confer holds a BS in finance and legal studies from Bloomsburg University of Pennsylvania and an MS in technology commercialization from the McCombs School of Business at the University of Texas at Austin.

Jan Stevens, RN, is vice president of Clinical Operations. Stevens has nearly 20 years of comprehensive clinical operations experience in the biopharma industry and a specialization in early-to-late stage oncology companies. Stevens joined the company to help support the various clinical development programs for Oncoprex™.

Genprex Inc. (NASDAQ: GNPX), closed Thursday's trading session at $0.9637, up 1.1865%, on 22,170 volume with 54 trades. The average volume for the last 3 months is 39,845 and the stock's 52-week low/high is $0.640999972/$2.75.

Recent News

chart

Standard Lithium Ltd. (TSX.V: SLL) (FRA: S5L) (OTC: STLHF)

The QualityStocks Daily Newsletter would like to spotlight Standard Lithium Ltd. (OTC: STLHF).

Standard Lithium Ltd. (TSXV: SLL) (OTCQX: STLHF) (FRA: S5L), is pleased to announce that the fabrication of Phases 1 & 2 of the Company’s “LiSTR” direct lithium extraction Demonstration Plant are complete, and that the initial modules are currently being transported to the project location at Lanxess’ South Plant facility in southern Arkansas (the “Site”). Standard Lithium is also pleased to confirm that all the Site construction works are on-schedule, and the concrete slab and foundations required to locate the Demonstration Plant have been completed.

Standard Lithium Ltd. (OTC: STLHF) is focused on unlocking the value of existing large-scale U.S.-based lithium brine resources that can quickly be brought into production. The Company believes new lithium production can rapidly be brought on stream by minimizing project risks at selection stage; resource, political & geographic, and regulatory & permitting; and by leveraging advances in lithium extraction technologies and processes.

The Company’s flagship project is in southern Arkansas. The more than 180,000-acre “Smackover Project” is in the most prolific and productive brine processing region in North America. Agreements with large commercial brine operators in the region will allow Standard Lithium to utilize the extensive existing infrastructure, including brine supply and disposal pipelines, water, power and a trained workforce to fast-track project development timelines.

“Arkansas produces about 9.4 billion gallons of brine per year, according to 2010-2016 average statistics reported by the Arkansas Oil & Gas Commission.”

Standard Lithium signed a binding MoU with global specialty chemicals company LANXESS Corporation and its U.S. affiliate Great Lakes Chemical Corporation with the purpose of demonstrating the commercial viability of extraction of lithium from brine (“tail brine”) that is produced as part of LANXESS’ bromine extraction business at its three Southern Arkansas facilities.

LANXESS’ land operations in Southern Arkansas encompass more than 150,000 acres, 10,000 brine leases and surface agreements and 250 miles of pipelines. LANXESS extracts the brine from its wells located throughout the area, and the brine is transported to the three Arkansas plants through a network of pipelines. The three bromine extraction plants currently employ approximately 500 people and process and reinject several hundred thousand barrels of brine per day.

Standard Lithium has developed a breakthrough rapid lithium extraction process that reduces the recovery time of extracting lithium from brine to as little as several hours vs. the current industry method that takes years. The process is also much more environmentally friendly with a significantly smaller footprint than the conventional processes. The company has a signed agreement to locate a demonstration scale lithium extraction plant inside one of LANXESS’ chemical plants in Southern Arkansas.

The Company has also signed an option agreement with NYSE-listed Tetra Technologies for the lithium rights for exploration, extraction, and possible commercial development on approximately 30,000 acres of brine leases in Southern Arkansas. The largest available land package.

Recent laboratory results of four brine samples recovered from two existing wells in Standard Lithium’s project area showed lithium concentrations ranging between 347-461 mg/L lithium, with an average of 450 mg/L lithium in one of the wells and 350 mg/L in the other. Geological modeling of the project area is complete, and a maiden resource report is on the horizon.

Market Opportunity

World demand for lithium continues to surge. The global lithium compounds market is projected to reach U.S. $5.87 billion by 2020 at a compound annual growth rate of 13.22% between 2015 and 2020. Lithium-ion batteries are the fastest growing segment of the market.

Leadership

Standard Lithium’s commitment to being a premier, innovation-driven company focused on developing and commercializing new modern processes for lithium extraction is bolstered by the leading experts that comprise the company’s Scientific Advisory Council. Each member was selected because of their experience and expertise in areas that are central to and/or complement Standard Lithium’s current development plans. Standard Lithium recently welcomed to the Council world-renowned chemist Dr. Barry Sharpless, the recipient of the 2001 Nobel Prize in Chemistry for his work on chirally catalyzed oxidation reactions.

Standard Lithium is led by a team of professionals with proven strong technical and project development skills. CEO Robert Mintak has a global network of industry contacts and is a pioneer in the rapidly evolving lithium space. COO and President Dr. Andy Robinson is an experienced geoscientist with 20+ years of experience and a PhD in Geochemistry from the University of Bristol, UK. Dr. Robinson has worked on a wide range of projects in the resource, power and energy sectors in Europe, Africa, and North and South America.

The company recently appointed Robert Cross as non-executive chairman. Cross is an engineer with 25 years of experience as a financier and company builder in the mining and oil and gas sectors. He co-founded and serves as chairman of B2Gold, a top-performing growing gold producer which is expected to achieve nearly 1 million ounces of low-cost gold production in 2018. He was also co-founder and chairman of Bankers Petroleum Ltd.; co-founder and chairman of Petrodorado Energy Ltd.; and until October 2007 was the non-executive chairman of Northern Orion Resources Inc. He also was previously the chairman and CEO of Yorkton Securities Inc., and a partner in investment banking with Gordon Capital Corp. in Toronto. Cross has an engineering degree from the University of Waterloo (1982) and received an MBA from Harvard in 1987.

Following a multi-million-dollar financing in Q1 2018, Standard Lithium is well-positioned to meet its upcoming milestones including two maiden resource reports and the launch of its breakthrough rapid lithium extraction technology.

Standard Lithium Ltd. (OTC: STLHF), closed Thursday's trading session at $0.65, up 1.5625%, on 29,991 volume with 18 trades. The average volume for the last 3 months is 40,544 and the stock's 52-week low/high is $0.483999997/$1.38740003.

Recent News

chart

Nabis Holdings (CSE: NAB) (OTC: NABIF) (FRA: 71P)

The QualityStocks Daily Newsletter would like to spotlight Nabis Holdings (OTC: NABIF).

Nabis Holdings Inc. (CSE: NAB) (OTC: NABIF) (FRA: 71P) is working toward its strategic investment goal through a recently announced 49 percent acquisition of Cannova Medical Ltd., a provider of innovative solutions for cannabis consumption (http://nnw.fm/F5Ck6). Nabis aims to enter numerous facets of the cannabis sector, including the creation of related technology, according to Nabis director and CEO Shay Shnet.

Nabis Holdings (CSE: NAB) (OTC: NABIF) (FRA: 71P), dba Innovative Properties Inc., is a Canadian investment company pursuing interests in high-quality cash-flow assets in real property, securities, cryptocurrency and all branches of the cannabis sector. The company's focus on strategic revenue generation, EBITDA and growth is enshrined in its moto, "One team. One goal," and is reflected in its name: "Na bis," which is defined as, "repeat performance" or "encore."

Strategy

While the Nabis' targets span numerous industries, the company aims to establish an Anchor Investment Portfolio primarily through the acquisition of majority interests in high quality U.S. cannabis assets and brands that have achieved cash flow. The company will then employ a hands-on approach to assist the investee in implementing standards and consistency to enhance their operations.

Criteria for investment targets are as follows:

  • Positive EBITDA, vertically integrated operators in limited license states with large addressable markets
  • Emphasis on operations that add material EBITDA within 12 months with enhanced access to capital and Nabis' value add approach on operations and brand consistency
  • Identifying proven operators with good expertise to add value to a consolidation strategy
  • Focused on MSOs (Multi-state Operators) with strong brand traction
  • Pharma grade cultivation, extraction, dispensaries and other addressable operations

Current Endeavors

Nabis has completed investments in five Michigan properties with Cannabis provisioning, processing and cultivation licenses. The Company has also entered into binding Letters of Intent ("LOI") to invest in vertically integrated assets in Michigan, Arizona and Washington State. The company's goal is to be invested in four to five additional states in the coming months.

Arizona – LOI to acquire full control of Organica Patient Group Inc. ("OPG") and RDF Management Group. OPG is a fully integrated medical marijuana business licensed under the provisions of the Arizona Medical Marijuana Act. Its assets include the Chino Valley MMJ Dispensary and fully established Patient Group, which since 2012 has operated as "Organica Patient Group" in Chino Valley. OPG also operates a 26,000-square-foot indoor cultivation and processing center along with a 56,600-square-foot greenhouse in Prescott Valley; has its own branded products and wholesale operations which includes distribution to more than 25% of the dispensaries in Arizona; and has exclusive manufacturing and licensing agreements with Fire Brand, Gas Extracts and Donuts Concentrate products distributed within Arizona.

Michigan – LOIs to invest in multiple strategically located properties that have or are eligible for municipal approvals for provisioning centers in Michigan. The company is currently evaluating 10 to 15 additional municipally approved locations in Michigan that would substantially increase the company's overall presence in the U.S. cannabis space.

Washington State – LOI to purchase assets from PDT Technologies LLC, including extraction and production equipment and rights to lease the current production facility in Port Townsend, Wash. The LOI includes licensing rights to produce Chong's Choice Brand CO2 Vape Cartridges, one of the leading and most recognizable brands in the cannabis space. Expansion plans include construction of a new ISO designed extraction clean room and GMP lab facility with new, highly specialized equipment with two extraction lines. The facility could produce up to 20,500 kg of cannabis concentrate on an annual basis.

Hivemind Refinery – LOI to invest in a 70% interest of Hivemind Refinery, an established line of CBD-based wellness products in the United States. The investment into Hivemind expands Nabis' investment portfolio to CBD edibles, water, drops, lotions, and other CBD wellness products across the spectrum. Nabis anticipates Hivemind will be a premium consumer CBD line to be distributed across the U.S. and Canada and will focus on products utilizing locally grown, premium CBD along with unique formulations and delivery systems.

Bloombox – binding term sheet with Momentum Ideas Co. to acquire certain assets used and marketed under the brand "Bloombox," a leading intelligent retail cannabis software platform that includes the Bloombox Software and data platform. The acquisition of Bloombox will create a dominating presence in the U.S. cannabis market, featuring an integrated ecosystem of modern, next-generation cannabis technology. Bloombox is one of the world's first standards-based cannabis software systems, enabling frictionless integration with nearly any business system or regulatory body.

Proven Management Team

CEO and Director Shay Shnet has over 20 years of experience in business and was most recently a founding partner and vice president of operations of MPX Bioceutical (CSE: MPX). While at MPX, Shnet focused on the North American cannabis space and helped build the company's portfolio of international cannabis assets. He is highly skilled in finding unique opportunities and has been directly involved with the development, branding, importing, consumer packaging and distribution of a wide variety of product lines.

President Mark Krytiuk is a very successful cannabis operator and was a founding partner of MPX. As the vice president of grow operations of MPX, he oversaw the production of medical marijuana and pharma-grade products across North America. He has been directly involved in overseeing the rapid expansion and buildout of nine facilities in three countries with budgets ranging up to $30 million. Krytiuk's experience includes consulting and working with customers to develop individual requirements for indoor and outdoor cannabis cultivation while working with federal regulators and licensing bodies to ensure compliance.

Nabis Holdings (OTC: NABIF), closed Thursday's trading session at $0.1554, up 3.60%, on 90,827 volume with 12 trades. The average volume for the last 3 months is 50,325 and the stock's 52-week low/high is $0.119249999/$0.791499972.

Recent News

chart

Spectrum Global Solutions, Inc. (SGSI)

The QualityStocks Daily Newsletter would like to spotlight Spectrum Global Solutions, Inc. (SGSI).

Spectrum Global Solutions (OTCQB: SGSI), a leading single-source provider of next-generation communications network infrastructure and maintenance solutions, this morning announced its recent receipt of $3.6 million in new contract awards across all operating subsidiaries. Per the update, the contracts consist of work orders from both new and existing clients and are predominantly for infrastructure projects as network operators prepare for a nationwide implementation of 5G. To view the full press release, visit: http://nnw.fm/ix1JE.

Spectrum Global Solutions, Inc. (SGSI) is a leading single-source provider of end-to-end, next-generation wireless and wireline network infrastructure services and staffing solutions to the service provider (carrier) and corporate enterprise markets across the United States, Canada, Puerto Rico, Guam and the Caribbean. Spectrum Global Solutions provides services directly to carriers, aggregators, utilities, enterprise, Project Management Organizations (PMO) and Original Equipment Manufacturers (OEM) clientele through the following subsidiaries:

  • AW Solutions, Inc. and AW Solutions Puerto Rico, LLC – Provides best-in-class communications infrastructure deployment services to carriers, OEMs, PMOs, utilities and enterprise clients by offering discrete and full turnkey service solutions for wireless and wireline clientele. AW Solutions holds professional engineering licenses in all contiguous states and in the District of Columbia and Hawaii; the Canadian provinces of British Columbia, Quebec, Ontario, Alberta and Newfoundland and Labrador; in Puerto Rico, Guam and the U.S. Virgin Islands.
  • ADEX Corporation and ADEX Puerto Rico, LLC – An international service organization providing turnkey services and staffing solutions to telecommunications carriers and enterprise clients. Since 1993, ADEX has been assisting telecommunications companies throughout the project life cycle of any network deployment. ADEX and its service capabilities extend from the most basic installation functions to the most advanced engineering disciplines for today and tomorrow’s communications networks. Headquartered in Atlanta, Georgia, ADEX employs technical professionals and provides infrastructure services worldwide via domestic and international locations.
  • Tropical Communications, Inc. – A state licensed electrical and underground utility contractor headquartered in Miami, Florida, providing all types of communications and infrastructure facility structured wiring services and solutions since 1984.

Through its subsidiaries, Spectrum Global Solutions is a comprehensive single-source provider for professional services and solutions for the development, deployment and maintenance of wireless/Distributed Antenna System (DAS)/small cell/wireline and fiber networks and infrastructure. The company’s services range in scope from a single activity to multiyear, multi-region, large-scale turnkey development contracts with a deepening pool of international, national, regional and local projects. Spectrum Global Solutions has completed more than 150,000 project activities on wireless, DAS, wireline and fiber networks across the United States utilizing licensed professional engineers, project managers, technicians and general contractors.

Market Opportunity

Growth projections for the telecom industry show a high growth cycle 2018 through 2025 with a four-fold increase in domestic mobile data traffic and up to $150 billion in fiber investment over the next 5-7 years (Deloitte, 2017). The worldwide explosion of smart phones, tablets and BYOD by customers demanding rapid deployment of new apps, private networks with better coverage and enhanced capacity provides a compelling enterprise opportunity market. The imminent rollout of 5G next generation networks, IOT (Internet-Of-Things) technology deployments, the FirstNet national public safety system, small cell/network densification, Dish Network Deployment, fiber and infrastructure network builds for backhaul and expanded deployments, new FCC spectrum auctions and upgrades to 4G, DAS and small cell networks are contributing to a projected $157 billion in U.S. telecommunication carrier capital expenditures by 2021.

Management

CEO Roger Ponder has served as a director of Spectrum Global Solutions since April 2017. Ponder served as President/CEO of Summit Capital Advisors, LLC, and Summit Broadband, LLC a provider of consulting services to private equity and institutional banking entities in the telecommunications, cable and media/internet sectors. He also served as a member of the board of directors of InterCloud Systems, Inc. and served as its Chief Operating Officer from November 2012 to March 2015. Prior to that Ponder retired from Time Warner Kansas City Division as President/CEO. Ponder brings extensive business development, strategic planning and operational experience to the Company.

Keith Hayter is President of Spectrum Global Solutions and has served as a director of the Company since April 2017. Hayter has also served as the Chief Executive Officer and President of AW Solutions Inc. and AW Solutions Puerto Rico LLC since November 2006. He was Vice President and General Manager of Alcoa Wireless Services from 2001-2006. Hayter served in both the U.S. and British armies and brings extensive multi-national experience in the start-up, development, management and growth of companies in the telecommunication, engineering and construction industry.

Spectrum Global Solutions, Inc. (SGSI), closed Thursday's trading session at $0.064, up 6.6667%, on 83,850 volume with 4 trades. The average volume for the last 3 months is 59,061 and the stock's 52-week low/high is $0.032000001/$2.5999999.

Recent News

chart

Sugarmade, Inc. (SGMD)

The QualityStocks Daily Newsletter would like to spotlight Sugarmade, Inc. (SGMD).

While the huge increase in U.S. consumer demand from hemp extracts and hemp product is largely credited as the reason for the boom in the number of hemp acres under cultivation, there is a significant additional part of the hemp-growth story to tell. With a pending acquisition in the cultivation supply market, Sugarmade Inc. (OTCQB: SGMD) (SGMD Profile) appears to be well poised to become a strong pick-and-shovel provider to the hemp industry. Even the large cultivators and suppliers are now getting in the hemp market.

Sugarmade, Inc. (SGMD), one of the largest publicly traded hydroponics supply companies moving into the industrial hemp space, is a product and brand marketing company investing in products and brands with disruptive potential. Sugarmade’s brands include: ZenHydro.com; CarryOutSupplies.com; and BudLife. Headquartered in Monrovia, California, a city within Los Angeles county, Sugarmade has various business operations in diverse marketplaces including packaging and paper goods for various industries, agricultural supplies.

Sugarmade has expanded into the European hydroponics supply market with a growing base of orders taken through Amazon UK. Over the past few financial quarters, Sugarmade has seen revenue growth patterns expand geographically. As recently as mid-2017, the majority of hydroponic-related revenue growth was seen from California and other West Coast marketplaces, however growth is becoming more geographically dispersed among U.S. states where legalization has eased restriction. This movement into the United Kingdom further expands the base of geographic growth areas for Sugarmade.

Sugarmade recently launched a new corporate initiative in the booming industrial hemp and CBD, committing up to $1 million in capital over the next 12 months to invest in Hempistry, Inc., a privately held Nevada corporation. Hempistry has begun planting an ultra-high cannabidiol (CBD) industrial hemp strain on a land option it holds on 23,000 acres of prime Kentucky farmland. The strain of industrial hemp being grown by Hempistry is ultra-rich in CBD but contains less than 0.3 percent of THC, the psychoactive ingredient found in cannabis. The U.S. hemp industry is expected to produce well over $1 billion in revenues in 2018, with a compound annual growth rate of 14 percent through 2022, according to the Hemp Business Journal.

Demand for industrial hemp and products derived from hemp is soaring, with no let-up in sight, which the company sees as a “tremendous opportunity to become a supplier to this fast-growing sector,” said Chairman and CEO Jimmy Chan, who is also an advisor and minority shareholder of Hempistry.

Sugarmade’s investment into the market for high-CBD hemp is expected to be highly accretive for common shareholders in two ways. First, Sugarmade’s investment will be in the form of common shares in Hempistry allowing Sugarmade common shareholders to possibly benefit from any future initial public offering of Hempistry. Second, Sugarmade is expected to sign a supply agreement with Hempistry for cultivation supplies, which would be additive to corporate revenues.

Sugarmade has also completed a master market agreement with industry leader BizRight Hydroponics, Inc., a leading marketer and manufacturer of cannabis and hydroponic growth supplies, which offers a range of hydroponics-related products including: HPS grow lights, electronic ballasts, HPS bulbs, nutrient mixes, environmental control products, pH measurement and calibration solutions and storage products. BizRight operates the ZenHydro.com website and other e-commerce properties and sells various products to distributors and retailers. BizRight is expected to produce in excess of $30 million in revenues during 2017, with substantial growth expected for 2018.

Sugarmade division CarryOutSupplies.com, the leader in paper and plastic take-out supplies, serves nationwide customers by offering a wide array of high quality products that are cost-efficient, custom-made and delivered on time. This business unit currently serves 2,000 quick service restaurants, garnering from 30-40 percent of the market share. Sugarmade plans to expand operations via the addition of market share and the introduction of new product offerings.

Management

CEO Jimmy Chan is an experienced business executive instrumental in growing multiple business operations with a strong expertise in international trade and banking, and international manufacturing and importation. He is also the founder of CarryOutSupplies.com, a company that revolutionized the custom-printed paper supplies subsector of the quick service restaurant industry, which merged with Sugarmade in 2014.

Arman Tabatabaei serves as operations consultant, providing high-level, day-to-day strategic guidance and tactical operational supervision for all aspects of the corporation’s business. He is an expert at data collection and analysis relative to resource management, risk forecasting and profit and loss management.

Sugarmade specializes in growing and acquiring innovative brands to maximize value for company employees, shareholders and other stakeholders. Sugarmade believes its future is very bright as the company expands operations within the cultivation sector and rapidly increases its revenue base. 6

Sugarmade, Inc. (SGMD), closed Thursday's trading session at $0.0159, up 20.4545%, on 9,485,311 volume with 224 trades. The average volume for the last 3 months is 3,799,156 and the stock's 52-week low/high is $0.00975/$0.197500005.

Recent News

chart

Sharing Services Global Corporation (SHRG)

The QualityStocks Daily Newsletter would like to spotlight Sharing Services Global Corporation (SHRG).

Sharing Services Global Corporation (OTCQB: SHRG) had a record year, establishing itself as an impressive performer in an industry that is itself seeing record numbers. The direct-selling industry reached its highest sales ever – topping out at $192.9 billion in 2018 – with sales up in 65 percent of the direct-selling countries around the world. Sales aren’t the only indicators of the sector’s strong and steady performance. The industry’s global independent sales force reached 118.4 million, with more than 13.8 million individuals joining the ranks of direct-sales firms since 2015 alone (http://nnw.fm/4oKQY).

Sharing Services Global Corporation (SHRG), headquartered in Plano, Texas, is a diversified holdings company focused on reshaping how entrepreneurs succeed today. Sharing Services Inc. owns, operates or controls an interest in a variety of companies specializing in the direct selling industry that either sell products to the consumer directly through independent representatives or offer services that range from health and wellness, energy, technology, insurance services, training, media and travel benefits. SHRG has created the “Blue Ocean Strategy,” which melds three keys together to implement the company’s vision. These keys include elevating home-based entrepreneurs, known as “Elepreneurs,” utilizing the direct selling channel to generate 100 percent organic growth.

Sharing Services Inc. subsidiaries include:

  • A growing international network of home-based entrepreneurs, called “Elepreneurs”
  • Growing selection of health and wellness products dedicated to elevating the well-being of all people
  • Insurance from auto, home and life to health benefit discounts and health insurance that help families elevate their options
  • Wholesale travel and payment programs with travel concierges that empower more families to go on vacation
  • Live seminars and training events – from Vacationars™ to EduTainment – that elevate the skills and knowledge of entrepreneurs around the world
  • Unique compensation and reward programs crafted to help entrepreneurs elevate their health, wealth and happiness

Sharing Services recently expanded its corporate footprint by moving to a 10,000 square foot facility in Plano, Texas, that offers room to expand as the company grows and its subsidiaries flourish. The larger corporate locale provides space for a growing customer service department, product fulfillment, opportunity and training rooms, as well as a video production suite.

“The opportunity to expand to the rest of this new building over the course of the next six to 12 months ensures we won’t have to move again anytime soon,” Sharing Services Inc. Chairman Robert Oblon said. “We are on track for very significant growth here in the U.S., as well as upcoming international expansion, so this move is in preparation for what’s in front of us.”

The company recently signed a joint venture agreement with Health Wealth & Happiness Limited (“HWH”) to expand its “Elepreneurs” brand and market its products throughout Asia. The newly formed company will be named “Elepreneurs Asia Limited” and will have marketing and sales rights to China, Hong Kong, Macau, South Korea, Japan, Taiwan, Cambodia, Indonesia, Laos, Malaysia, the Philippines, Singapore, Thailand, Vietnam and Papua, New Guinea. A soft launch of the Elepreneur program is scheduled sometime later in 2018 with HWH CEP Fai Chan and his team leading the effort. Formed in Hong Kong, Health Wealth & Happiness Limited is dedicated to working with visionary partners like Sharing Services Inc. to deliver the best products and services to improve the well-being of consumers.

Nearly 1,000 people attended Sharing Services Global Corporation ’s first “Elepreneur Happiness Convention,” held March 2-3, 2018, in Dallas, Texas. Attendees arrived from several countries including the U.S., Canada, Mexico, Singapore and Hong Kong. Keynote speakers included several internationally known motivational leaders – Shawn Achor, Sandra Yancey, John Fleming and Les Brown – who provided exceptional material and inspirational discussion points.

“The enthusiasm of our attendees and the early success that we are experiencing is incredible considering our growth has been 100 percent organic, with almost no marketing from the company,” Oblon said. “I’m speechless by the dedication of our Elepreneur leaders and their entire teams, as they share our incredible line of products that have helped so many people.”

Sharing Services and its management team plan to travel the U.S. to hold several mini conferences to expand on the messages presented at its Happiness Convention that focus on helping people become “healthier, happier and wealthier.” Details of the company’s aggressive global expansion initiatives are soon to be announced, Oblon said.

The law firm of Gardere Wynne Sewell LLP has been retained as outside corporate counsel for all general business matters. The Dallas-based law firm will represent Sharing Services Global Corporation , and its subsidiaries as the company utilizes the direct selling channel for a significant component of its overall growth strategy.

John “JT” Thatchwas appointed president and chief executive officer of Sharing Services Global Corporation , at a March 1, 2018, annual shareholder meeting. Thatch has successfully started, owned and operated several sized businesses in various industries. His experience with corporate growth, acquisitions, financing and negotiation in fast-paced and flexible environments will significantly assist Sharing Services Inc. as the company aims to expand and increase revenues.

Sharing Services Global Corporation (SHRG), closed Thursday's trading session at $0.16, even for the day, on 33,500 volume with 4 trades. The average volume for the last 3 months is 31,489 and the stock's 52-week low/high is $0.1026/$0.3944.

Recent News

chart

The Green Organic Dutchman (TSX: TGOD) (OTC: TGODF)

The QualityStocks Daily Newsletter would like to spotlight The Green Organic Dutchman (OTC: TGODF).

The Green Organic Dutchman Holdings (TSX: TGOD) (OTCQX: TGODF), a cannabis-focused research and development company, was recently named as one of the eco-friendliest cannabis firms in Canada. To view the full article, visit: http://nnw.fm/Do74R. Also today, the company was featured in the 420 with CNW by CannabisNewsWire. Last year Colorado marked four years of legal marijuana sales and the data from the state government shows a number of lessons that other states can learn from Colorado’s experience. Additionally, CannabisNewsWire released a report on the company detailing how an increasing number of U.S. farmers affected by low prices and reductions in Chinese agricultural purchases are now seeking economic refuge by planting hemp. And in many cases, hemp is saving farmers from bankruptcy.

The Green Organic Dutchman (TSX: TGOD) (OTC: TGODF), whose principal location is in Hamilton, Ontario, produces farm grown, organic, pesticide-free medical cannabis in small batches using all natural, organic craft growing principles. TGOD is licensed under the Access to Cannabis for Medical Purposes Regulations (ACMPR) to cultivate medical cannabis. The company carries out its principal activities producing cannabis pursuant to the provisions of the ACMPR and the Controlled Drugs and Substances Act (Canada).

Committed to becoming the global leader in delivering organic cannabis solutions that enhance people’s lives, TGOD consistently adheres to the highest levels of excellence. Its world-class management team includes a proven group of leaders with outstanding executive and operational experience specific to consumer packaged goods, consumer products, cannabis and finance industries.

TGOD is positioned as one of the highest quality and most cost efficient cannabis producers in Canada by leveraging innovative technology and low-cost power solutions. It holds one of the largest land packages under a single ACMPR license in Canada, providing future cannabis Agri-park style development and opportunities for joint ventures, licensing and distribution partners. Its industry leading alliance partners include Eaton, Ledcor Group and Hamilton Utilities Corp.

Eaton is the second largest power management company in the world and promises to supply innovative and cost effective power solutions to meet TGOD’s growing demands. Construction management is supplied by Ledcor, Canada’s second largest multidisciplinary construction company and a pioneer in the Green Building Industry. An alliance with Hamilton Utilities Corp allows TGOD to reduce its power costs from $0.13 per kWh to less than $0.05 per kWh. Greenhouse design is provided by Larssen Greenhouse, whose 25-plus years of experience in building some of the most modern and sophisticated greenhouses in the industry will provide TGOD with state of the art, climate-controlled hybrid greenhouse solutions.

Canada is quickly becoming a hub for cannabis investors with over $1.3 billion raised by Canadian companies to date. There are 58 licensed producers to service a population of 36 million and only two organic producers. TGOD, which holds licenses in Ontario and Quebec, is strategically located in both provinces that together claim 22 million Canadians as residents. Another estimated 57 million people live next door in six U.S. bordering states.

The Canadian cannabis market currently has a massive supply demand gap, which makes TGOD’s expansion plans even more important to investors. These plans include a combined build-out capacity of 970,000 square feet, allowing TGOD to produce 116,000 kg annually of organic cannabis. Upon completion, Phase One in Hamilton, Ontario, which is fully funded, will provide 150,000 square feet of growing capacity capable of producing up to 14,000 kg of cannabis or $112 million in revenue at $8 a gram.

The company’s Quebec expansion will be constructed on a recently secured 75-acre property near Montreal. This new property has a planned expansion of 820,000 square feet capable of producing 102,000 kg of organic cannabis. The first phase of this expansion is underway and construction is expected to be completed by the end of 2018. Quebec’s first phase will consist of 220,000 square feet capable of producing 22,000 kg of cannabis. Two additional expansion phases will add 250,000 square feet (26,000 kg of cannabis) and 350,000 square feet (54,000 kg of cannabis). Power costs remain exceptionally low for both facilities with access to all other needed utilities available and close by.

TGOD also plans to gain a share of the burgeoning cannabis oils market which by Q1 2017 accounted for 49 percent of all cannabis sold in Canada under the ACMPR, up from only 27% in Q2 2016. TGOD has ordered a purpose-built extraction laboratory with an estimated commission in Q4 of 2017. This is a commercial-scale CO2 extraction unit capable of processing up to 12,000 kg of raw material per year and producing approximately $170 million worth of organic cannabis oils. Raw cannabis oil provides a significant downstream manufacturing opportunity into several potential recreational market verticals including edibles, beverages, topicals and concentrates.

Data from the Canadian ACMPR Market Trends report indicates a rising number of consumers will continue to seek out healthier, less conspicuous ways to consume cannabis, ensuring sales of organic cannabis oil products remain brisk. Organic cannabis products demand a significant premium compared to non-organic products and the demand keeps growing.

Plans to take the company public are underway with an initial public offering (IPO) slated for January 2018. In November, the company raised $13 million in equity financing and in March closed a $27 million non-brokered private placement. Another $20 million is currently being raised before the IPO in January, which will be utilized for expansion plans.

TGOD is uniquely positioned between the medical and recreational cannabis industry since Canada is scheduled to legalize cannabis for all adults in mid-2018. As of August 2017, TGOD has 2,400 shareholders. Established in 2012, TGOD’s motto, “Making Life Better,” can be seen in its strategic partnerships, top quality management team, and dedication to organic farming and principles.

To learn more about the company and how to invest, contact TGOD directly at financing@tgod.ca

The Green Organic Dutchman (OTC: TGODF), closed Thursday's trading session at $2.44, off by 1.6129%, on 544,651 volume with 655 trades. The average volume for the last 3 months is 607,397 and the stock's 52-week low/high is $1.60699999/$7.89379978.

Recent News

chart

The Supreme Cannabis Company Inc. (TSX.V: FIRE) (OTC: SPRWF)

The QualityStocks Daily Newsletter would like to spotlight Supreme Cannabis Company Inc. (OTC: SPRWF).

The Supreme Cannabis Company Inc. (TSX: FIRE) (OTCQX: SPRWF) (FRA: 53S1) recently announced preliminary figures for the quarter ended June 30, 2019, and for its full fiscal year 2019 (http://nnw.fm/v97WP). Preliminary figures show sales of $19 million net of excise tax for the three-month period. The company also anticipates reporting positive adjusted EBITDA on a consolidated basis for the 12-month period. Also today, the company was featured in the 420 with CNW by CannabisNewsWire. It wasn’t just hype when marijuana legalization advocates campaigned on the promise that legalizing marijuana would be good for the economy. Colorado’s data reveals that cannabis sales amounting to more than $6 billion were recorded between 2014 and 2018. These sales resulted in tax revenue exceeding $1 billion, and the state coffers are the better for it.

Supreme Cannabis Company Inc. (TSX.V: FIRE) (OTC: SPRWF), is committed to providing premium brands and products that reflect the company’s knowledgeable customers, passionate employees, and culture of innovation. Supreme Cannabis’ mission is to grow the world’s best cannabis and become a leader in the global industry. The company calls its Toronto Venture Exchange stock symbol FIRE “a testament to our passion for cannabis and our obsession with quality.”

Supreme Cannabis believes the world is ready to follow Canada’s lead by ending the 100-year cannabis prohibition and, as Canada’s only coast-to-coast premium cannabis producer, the company sees itself at the center of this global shift.

In August 2018, Supreme Cannabis uplisted its shares to the to OTCQX market in the U.S., where the company trades under the ticker symbol SPRWF. The following month Supreme reported record Q4 revenues of CAD$3.55 million, a 71-percent increase over the previous quarter. Supreme Cannabis also recorded revenue of CAD$8.85 million for its fiscal year ended June 30, 2018, placing it among publicly traded Canadian cannabis companies with the highest reported revenue in their first four quarters of sales.

“As a result of the successful execution of our strategy, we have generated significant revenue growth both for the quarter and the year-end period,” Supreme Cannabis CEO Navdeep Dhaliwal stated in a news release. “We look forward to building on this growth as we expand domestically and internationally.”

The company’s growth strategy includes key industry agreements, such as its CAD$12 million supply agreement with Tilray Inc. (OTC: TLRY), a global leader in cannabis research, cultivation, processing and distribution. The agreement calls for Supreme to supply Tilray with dried cannabis for support of medical cannabis patients in Canada for the period of one year.

Another key component is the company’s wholly owned 7ACRES subsidiary. The 7ACRES cultivation facility, one of the first 40 federally licensed cannabis producers in Canada, is focused on building a core competency in scaled cannabis production, which will give 7ACRES the needed flexibility to maintain leadership in the industry as the Canadian market grows and matures. Though 7ACRES is Supreme Cannabis’ flagship brand and only currently operating business unit, the company will continue to identify new opportunities to grow its portfolio of companies and build innovative cannabis businesses throughout the world.

7ACRES operates from a 342,000-square-foot cultivation facility in Kincardine, Ontario, and has been federally licensed since 2016. Current capacity is 13,333 kilograms dried cannabis annually, with plans to ramp up production by mid-2019 to a rate of 50,000 kilograms per year.

Supreme Cannabis seeks to differentiate 7ACRES from other licensed cannabis producers by producing premium quality product sustainably at scale. “Craft quality, commercial scale” is a slogan the company uses, and the Kincardine greenhouse employs state-of-the-art technology and cultivation best practices to strive toward that goal. Supreme identifies the quality of the 7ACRES product as the company’s primary strength and says a shared “passion for the plant” is the driver of company culture. Six Canadian provinces have signed supply agreements with Supreme, a fact the company credits to the high quality of 7ACRES cannabis.

Its customers, Supreme Cannabis management says, are informed and discerning regarding cannabis, and they value a premium brand that respects their product knowledge. The company believes its high regard for customers, premium product quality, and mass cultivation capability has allowed Supreme Cannabis to emerge as Canada’s preeminent premium cannabis producer. In the Canadian cannabis market, the company has established 7ACRES as a premium brand that’s distributed coast-to-coast and commands premium pricing. The 7ACRES brand is already listed as premium cannabis product in all provinces that disclose their cannabis listing categories, and 7ACRES on average wholesales for up to one-third higher in price than other brands in the Canadian cannabis market.

To further its distribution, in the medical cannabis market Supreme Cannabis has partnered with several Canadian cannabis retailers including Aurora Cannabis, Emerald Health Botanicals, Namaste, Zenabis, and others. The company’s investment portfolio also includes an equity position and long-term global distribution partnership with Medigrow, based in Lesotho, targeting the export of medical cannabis oil for the international market.

Supreme Cannabis seeks to make the company an innovator in the cannabis sector regarding design of cultivation facilities and development of operation excellence metrics. The management team is confident that the 7ACRES flagship brand, the company’s proprietary technology and products, and the company’s culture of passion for cannabis will deliver consistent long-term shareholder value.

Supreme Cannabis Company Inc. (OTC: SPRWF), closed Thursday's trading session at $1.13, off by 6.6116%, on 420,525 volume with 396 trades. The average volume for the last 3 months is 473,660 and the stock's 52-week low/high is $0.850000023/$2.03999996.

Recent News

chart

Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP)

The QualityStocks Daily Newsletter would like to spotlight Lexaria Bioscience Corp. (LXRP).

Lexaria Bioscience Corp. (OTCQX:LXRP) (CSE:LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce the online commercial launch of ChrgD+, the industry’s most advanced water-soluble multi-spectrum hemp oil in a powdered format and empowered with DehydraTECHTM for fast, effective delivery. For sale now to US consumers at chrgd.life

Lexaria Bioscience Corp. (CSE: LXX) (OTC: LXRP) has developed and out-licenses its proprietary technology for improved taste, rapidity, and delivery of bioactive compounds, including nicotine and cannabinoids. To achieve higher absorption rates and fast onset, consumers traditionally defaulted to smoking. Lexaria provides a superior administration method by delivering these substances through a patented process within edible food products, thus eliminating all the harmful health consequences of smoking.

Lexaria’s technology is unique in that it takes advantage of GRAS (Generally Recognized As Safe) food ingredients processed with its patented DehydraTECHTM technology to improve taste, remove odor, and decrease the time to onset of bitter-tasting drugs. Lexaria is primarily a B2B enterprise and has existing cannabinoid licensing agreements with companies in Canada, the largest-market states in the United States, and internationally. Lexaria has entered into a R&D partnership with one of the largest cigarette companies in the world for oral forms of nicotine delivery. Lexaria has also developed its own brands partly for demonstration purposes, utilizing its patented technology to infuse hemp oil ingredients within popular foods such as coffee, tea, and supplements. These brands include ViPova™ and TurboCBD™.

In 2015, Lexaria commissioned an independent third-party lab to test its technology under carefully monitored in vitro conditions. Results showed that the company’s technological process and lipid formulation improve intestinal absorption as much as 500%. Lexaria has conducted multiple rounds of studies including in vivo and human clinical. In absorption studies conducted on rats, for example, Lexaria detected nicotine in the animal’s bloodstream just two minutes after it entered the stomach. In a randomized, double blinded human clinical study, cannabidiol (CBD) was measure in the human bloodstream at a 317% higher rate 30 minutes after swallowing a capsule processed with DehydraTECH than a non-enhanced capsule of equal strength.

Lexaria also has an R&D partnership with the Canadian government’s National Research Council. That R&D is expected to characterize molecular bond formation theorized to occur with Lexaria’s unique technology between the lipid delivery agents and the bioactive substances it processes and combines. Results from this R&D have helped support B2B relationships with Fortune 500 companies. Lexaria has four distinct subsidiaries that focus on different market sectors: Hemp/CBD; Pharmaceutical; Cannabis; and Nicotine.

Aside from testing, a critical component of Lexaria Bioscience’s business model is a strong and growing intellectual property portfolio. As of the end of 2018, the company’s patent portfolio includes 53 patent applications filed and pending in more than 40 countries around the world; and 10 patents granted to date. Lexaria is expecting additional new patent awards both in the U.S. and internationally in 2019 and beyond. Some of its more recent areas of investigation have included human hormones and erectile dysfunction substances, among others.

Royalties play a vital role in Lexaria’s revenue-generating business model. The company out-licenses its technology (royalty) to third-partners and has signed royalty deals with start-up companies as well as with a Fortune 100. The company’s growth initiatives are guided by a management team headed by CEO Chris Bunka, a serial entrepreneur who has contributed to several multi-hundred million-dollar valuations over the course of his career. He is supported by a growing team of professionals with extensive experience in pharmaceutical and bioscience sectors, invention, toxicology, consumer goods, and other relevant skillsets.

Lexaria Bioscience Corp. (LXRP), closed Thursday's trading session at $0.73, off by 6.1214%, on 63,521 volume with 82 trades. The average volume for the last 3 months is 86,135 and the stock's 52-week low/high is $0.600000023/$2.24.

Recent News

chart

Grapefruit Boulevard Investments Inc. (IGNG)

The QualityStocks Daily Newsletter would like to spotlight Grapefruit Boulevard Investments Inc., the wholly owned subsidiary of Imaging3 Inc. (IGNG).

California-based Grapefruit Boulevard Investments, a wholly owned subsidiary of Imaging3 (OTCQB: IGNG), this morning announced its August 21, 2019 receipt of the initial comment letter from the SEC Division of Corporation Finance. To view the full press release, visit: http://nnw.fm/2FxZf.

Grapefruit Boulevard Investments Inc., a California corporation (“Grapefruit”), as of May 31, 2019, is a wholly owned subsidiary of Imaging3 Inc. (OTC: IGNG), a Delaware corporation whose shares of $.001 par value common stock are publicly traded on the OTCMarkets OTCQB Market under the symbol “IGNG.” IGNG is subject to the reporting requirements of the Securities Exchange Act of 1934 and files annual and quarterly reports pursuant thereto. Grapefruit holds licenses originally issued by the State of California in January 2018 to both manufacture and distribute cannabis products. Grapefruit’s management now owns a controlling interest in IGNG which now owns 100% of Grapefruit’s outstanding shares. As a result, IGNG’s financial reports will consolidate both IGNG’s and Grapefruit’s balance sheet, statement of operation and statement of cash flows and IGNG and Grapefruit will be operated as a single company. IGNG intends to change its name to Grapefruit and to obtain a more appropriate trading symbol as soon as possible. Hereinafter the combined companies will be referred to as “Grapefruit” or the “Company.”

Grapefruit’s corporate headquarters is in Westwood, Los Angeles, California. Grapefruit holds licenses to both manufacture and distribute cannabis products which were originally issued in January 2018 and is fully compliant with all applicable laws and regulations to operate its cannabis manufacturing and distribution businesses.

The company is well-focused on sourcing only the “best of the best” raw cannabis materials to create the highest quality, most-trusted and consistent recreational and medical cannabis products for its customers. Grapefruit is committed to ensuring class-leading quality by rigorously testing the purity and potency of its raw materials throughout the manufacturing process and distribution chain.

Grapefruit owns and operates its fully licensed and compliant ethanol extraction laboratory located in the Coachillin’ Industrial Cultivation and Ancillary Canna-Business Park in Desert Hot Springs, California. The company’s extraction lab produces high quality, cannabis-derived distillate, also known as “honey oil,” from cannabis flower and “trim.” THC honey oil is one of base cannabis commodities which serves as the active ingredient in everything from infused edibles and tinctures/creams to the cartridges used in vapes and e-cigarettes. Honey oil often sells on the wholesale marketplace for thousands of dollars per liter, with pricing being dependent on quantity purchased, as well as other market factors such as the availability and cost of the underlying flowers and/or trim.

Grapefruit began its extraction operations in May 2019. Plans are in place to expand its honey oil production through the purchase of additional distillation equipment, which is expected to significantly increase the company’s production capacity by the fourth quarter of 2019. Grapefruit’s extraction lab is fully scalable and expansion will be built-out on a two-acre lot owned by Grapefruit at the Coachillin’ site adjacent to its current manufacturing and distribution operation.

Grapefruit selected the City of Desert Hot Springs for its cannabis extraction laboratory, because the city has created a friendly business environment for cannabis-based manufacturers, including incentives like the absence of taxes on cannabis oil production revenues. This affords Grapefruit a fundamental competitive market advantage over other Honey Oil producers.

The California cannabis regulatory scheme is unique in that it requires all cultivators (cannabis farms) and manufacturers (whether producing oils/distillates, infused edibles, tinctures creams or other cannabis products) to sell their products into the legal cannabis wholesale and retail markets exclusively through licensed distributors such as Grapefruit. Grapefruit initially obtained its California recreational and medicinal cannabis distribution license Jan. 4, 2018. In May 2019, Grapefruit was granted its provisional distribution license which is renewable annually, thereby cementing the regulatory foundation necessary to rapidly expand its distribution business.

Grapefruit’s distribution license affords it a twofold strategic advantage: first, to market and sell its own cannabis product lines to retailers throughout California; and second, to buy and resell bulk cannabis flowers and trim as well as all other legal cannabis products to properly licensed distributors and/or retailers throughout California.

The Coachillin’ Canna-Business Park, home to Grapefruit’s current operating facilities and adjacent two-acre parcel of land, is a 160-acre, self-contained legally mapped compound providing the Company with a fully permitted and serviced physical plant from which Grapefruit intends to establish a leading position in the booming California cannabis sector. The parcel was purchased by the Company prior to the Park’s full development, and the value of the land the Company owns has conservatively since doubled in value to over $2 million. Additional long-term benefits of the Coachillin’ compound include agricultural rates for power, which are currently $0.09 per kilowatt hour; the Park’s deep-water well that fully satisfies its need for water; and security expenses shared by all resident businesses. The Coachillin’ Park’s promoters also plan to position the Park, located only 10 miles north of rapidly growing uptown Palm Springs and less than 15 miles from the site of the Coachella and Stagecoach music festivals as a must-see canna-tourism destination.

Grapefruit’s ultimate goal is to become a vertically integrated, seed-to-sale cannabis and CBD product company serving the California market. Moreover, it plans to roll-out its product lines in other states, such as Nevada, Illinois, Oregon, Colorado and Washington. Grapefruit has plans to build a large, all-inclusive facility that will house a 50,000-square-foot-plus indoor grow canopy, a large extraction laboratory designed to extract both THC and CBD cannabinoids via non-volatile (ethanol) and volatile (butane) processes, a manufacturing space to produce Grapefruit’s vape lines and CBD products, an FDA-certified kitchen for the production of Grapefruit edibles and a distribution facility to sell all products into the entire cannabis market. The indoor grow canopy operation will be outfitted and operated to produce ultra-high-quality flowers and buds, some of which, along with the high-quality trim resulting from cleaning and maintaining the grow, will provide biomass necessary to feed the company’s extraction laboratory. Fueled by this hand cultivated biomass, Grapefruit’s lab will continuously produce pesticide and heavy metal-free world class honey oil to both serve as the active ingredient in all of Grapefruit’s branded and unbranded products and meet the projected ever-growing demand for high quality honey oil in the California market.

Grapefruit’s motto – A High You Can Trust – embodies its philosophy and ethos, reminding consumers of the company’s commitment to manufacturing, procuring and distributing only the highest quality all-natural cannabis flower, concentrates and related products that are free from pesticides, heavy metals and bacteria. Grapefruit will target its products to all recreational cannabis enthusiasts’ as continuous, consistent cannabis products. By relentlessly adhering to these policies Grapefruit intends to become the Titleist of the Cannabis industry, known for unwavering quality and consistency.

Grapefruit is managed by a team of experts possessing the experience, skill and resources required to succeed in the competitive cannabis marketplace. Founded by brothers Bradley Yourist, CEO, and Daniel Yourist, COO, Grapefruit has expanded to become a group of industry professionals sharing a passion for all things cannabis. Both the CEO & COO are attorneys licensed to practice law the State of California who possess expert cannabis licensing and regulatory expertise and experience, which will allow Grapefruit to deftly navigate the ever changing California regulatory landscape and apply for new cannabis licenses at reduced costs when necessary, rather than having to acquire licenses that are often overvalued and/or pay outside counsel to handle such matters.

Grapefruit also has its own line of cannabis-infused concentrates and edibles. Among the brands now in stores or soon to be launched are:

  • Rainbow Dreams is a new lifestyle brand designed specifically for the recreational cannabis marketplace. The Rainbow Dreams brand captures the anything goes party vibe of the 1970s by offering an array of cannabis products, such as a line of vape carts with unique cannabis strains combined with all-natural flavors for a superior no-burn experience. Rainbow Dreams fills an important niche in the marketplace as a top shelf quality product line that is competitively priced.
  • Sugar Stoned, which Grapefruit acquired in the winter of 2018, has always been a popular cannabis edibles brand which terminated operations when recreational cannabis became legal and required a license in California. Grapefruit purchased the Sugar Stoned brand in 2019 and it is now a Grapefruit portfolio brand consisting of a premium quality cannabis-infused gummy line with eight different flavors: blue raspberry, cherry, grape, peach, pineapple, sour apple, strawberry and watermelon. Grapefruit intends to expand the brand in the near future through the release of a variety of infused cookies.

Grapefruit Boulevard Investments Inc. (IGNG), closed Thursday's trading session at $0.09993, off by 0.07%, on 238,755 volume with 27 trades. The average volume for the last 3 months is 115,424 and the stock's 52-week low/high is $0.006095/$0.358999997.

Recent News

chart

SinglePoint, Inc. (SING)

The QualityStocks Daily Newsletter would like to spotlight SinglePoint, Inc. (SING).

Technology and investment company SinglePoint (OTCQB: SING) recently announced that on Sunday, August 25, an interview featuring SING’s CEO Greg Lambrecht will air on The RedChip Money Report. To view the interview segment, visit: http://nnw.fm/DL8w5. To view the full press release, visit: http://nnw.fm/PSq0g.

SinglePoint, Inc. (SING) is a diversified holding company with operations in multiple industries and verticals including two high-performing market sectors: legal cannabis and cryptocurrencies. SinglePoint has grown from a full-service mobile technology provider to a recognizable brand with a diverse portfolio of undervalued subsidiaries with multiple revenue streams.

SinglePoint is researching opportunities where it can be an active participant by influencing the strategy and direction of high-potential companies whose verified assets offer attractive possibilities for shareholders. The company is guided by a visionary leadership team with extensive experience in technology, engineering, marketing and raising capital.

SinglePoint is bullish on the cannabis industry, bitcoin and blockchain technologies, which is evident in its recent acquisitions and joint-venture announcements. Recent SinglePoint key highlights include:

  • A joint venture with Smart Cannabis Corporation (OTC: SCNA) to license and market Smart Cannabis’ SMART APP. SMART APP enables cannabis growers to measure all aspects of cultivation, from soil nutrient levels to watering cycles and carbon dioxide content in the air. SMART APP will integrate SinglePoint’s bitcoin payment solution to enable growers to process safer and more secure transactions.
  • A joint venture with Global Payout (OTC: GOHE) will build on existing financial technology solutions developed by SinglePoint and Global Payout’s subsidiary MoneyTrac Technology, Inc., to fully optimize the delivery of mobile payment applications for domestic and international organizations.
  • A joint venture with AppSwarm (OTC: SWRM) to start development on a proprietary delivery application that will enable licensed cannabis delivery services and licensed dispensaries to safely make in-home cannabis deliveries.
  • Signed original “Shark Tank” member Kevin Harrington as company spokesman for an innovative, compatible virtual wallet to store any type of cryptocurrency. Harrington recently finished shooting a new national ad campaign featuring SinglePoint and the virtual wallet’s secure method of storing cryptocurrencies.
  • Entered into a letter of intent to acquire 100 percent of Bitcoin Beyond, a premier platform that enables merchants to accept bitcoin payments using existing web-enabled point-of-sale devices.
  • Through SING subsidiary, SingleSeed, the company will soon offer a proprietary cryptocurrency solution that links both cannabis merchants and consumers who seek to take advantage of bitcoin-powered transactions using debit and credit cards. In addition to making bitcoin-backed card purchases possible, the solution enables cannabis dispensaries to digitally track and manage their product inventories, performing tasks like uploading product data, photos and descriptions. The system deducts items automatically from a dispensary’s product listings when a purchase is made. While this fully KYC-AML compliant point-of-sale platform can be utilized for any other retail setting, it will fill a critical need in the underbanked cannabis industry as it continues to seek non-cash payment solutions outside of traditional banking circles.

SinglePoint CEO and founder Greg Lambrecht leads the company in its mission to capture opportunities through an aggressive expansion strategy across a broad range of assets. Lambrecht oversees all company operations including investor relations, leadership of the board of directors, and daily business activities. As the founder of PCI, a leading consumer product distribution company, Lambrecht negotiated agreements with the nation’s largest retail outlets and led PCI through a NASDAQ listed IPO, raising $10 million.

Eric Lofdahl, SinglePoint’s chief technology officer, has more than 20 years of experience in the technology sector including positions in software development, program management, complex system integration and engineering process definition. Prior to SinglePoint, Lofdahl worked at the Boeing Company where he led a team that successfully developed advanced wireless and satellite data products based on commercial technology for the U.S. Air Force.

SinglePoint President Wil Ralston is well known for his successful track record of building and maintaining great relationships with clients. Ralston graduated cum laude from the WP Carey School of Business at Arizona State University with a degree in Global Agribusiness and a specialization in Professional Golf Management. He is currently recognized by the Professional Golfers Association of America (PGA) as a Class A Professional.

SinglePoint, Inc. (SING), closed Thursday's trading session at $0.013, off by 3.7037%, on 2,418,801 volume with 82 trades. The average volume for the last 3 months is 3,393,906 and the stock's 52-week low/high is $0.009999999/$0.041000001.

Recent News

chart

Neutra Corp. (OTCQB: NTRR)

The QualityStocks Daily Newsletter would like to spotlight Neutra Corp. (NTRR).

Neutra Corp. (OTCQB: NTRR), an early stage research and development company focusing on modern healthy living solutions, has astutely taken advantage of several opportunities as the nation’s exploding CBD market begins to move into the general market retail sector. Two recent acquisitions are expected to accelerate Neutra’s corporate vision of bringing the highest quality, high potency hemp-based CBD extract products to retail customers.

Neutra Corp. (OTCQB: NTRR) is an early-stage research and development company bringing modern healthy living solutions to a multi-billion-dollar market. Cutting-edge technologies within the nutraceuticals, food and drug, and environmental purification sectors are creating a new kind of world culture – one where consumers are demanding access to products that promote health and stave off potential health dangers.

Neutra is concentrating on developing into a vertically integrated company able to cultivate, manufacture and distribute hemp-based cannabidiol (CBD) products. Hemp-based CBD consumer products generated sales of up to $390 million in 2018 with projections pointing to a $3 billion market by 2022, according to the Hemp Business Journal.

Neutra’s new broadened scope, which includes the commercialization of newer, more effective products, aims to capitalize on this worldwide boom. Our company is seeking new and exciting opportunities that can accelerate Neutra’s mission to bring these products to a wider demographic. Our work reflects a renewed dedication to supporting a better body, environment and life for people around the globe.

Acquisitions

  • Vivis – Neutra is expanding its market presence in the rapidly growing hemp-derived CBD market with a letter of intent to acquire Vivis, an emerging retail brand of hemp-based health and nutritional products. Vivis’ hemp-derived CBD products are third-party certified as contaminant-free and of consistent quality and potency. Consumers are increasingly looking for this certification when they buy hemp-based CBD products. With Vivis as the new retail face of Neutra, the company is expecting greater interest in its expanding portfolio of branded products moving to market.
  • J3 Holdings – The signing of a letter of intent to acquire J3 Holdings includes the company’s land and warehouse, as well as a license to cultivate hemp and refine it into usable forms. Neutra has concentrated its early efforts developing business networks and on developing hemp-based CBD products, including supplements and creams. The latest move will enable the company to grow its own hemp supply, giving it more control over the quality of its ingredients.

Partners

  • Surface to Air Solutions is the North American distributor of a patent-pending, water-based solution known as Purteq, a green technology that works similar to photosynthesis.
  • ZeroBlast uses a durable, non-toxic, anti-microbial solution to eliminate all contaminates and kill germs on contact for a period of up to 90 days.

Leadership

Neutra president and CEO Sydney Jim provides strong executive leadership, a network of business contacts and experience implementing solid corporate strategy. Jim has a proven track record of adding value for public company shareholders. He founded Global Visionary Investments where operational support is provided to seven different companies and their subsidiaries. Jim was also the CEO of First Titan Energy, a microcap public company where he was responsible for restructuring the corporate structure, deal sourcing, and leading the company in mergers and acquisitions.

Dr. Scott Cherry is the company’s sports performance medical advisor. He is an energetic physician executive with a passionate focus on health, performance and prevention. Dr. Cherry received emergency medical technician training in the U.S. Navy, a bachelor’s degree in chemistry from Florida State University, medical degree from Nova Southeastern University, and a master’s degree of public health from Uniformed Services University F. Edward Herbert School of Medicine. Dr. Cherry has honed his skills in a variety of medical and executive positions spanning the U.S. Army and Navy, several Fortune 500 corporations, and major health care facilities over the past 20 years.

Neutra Corp. (OTCQB: NTRR), closed Thursday's trading session at $0.0016, off by 11.1111%, on 6,433,835 volume with 19 trades. The average volume for the last 3 months is 20,333,111 and the stock's 52-week low/high is $0.0012/$0.14.

Recent News

chart

The QualityStocks Numbers Report

By The Numbers Chart

Top Performers


QualityStocksTwits

QualityStocksTwits is your stock tracking service portal to Twitter's universe of stock picks, commentary and research.

Visit Portal


The QualityStocks Sponsored News


The QualityStocks DailyNetwork Sponsors

ActionStockPicksAgressive StocksBetting On Wall StreetCannabisNewsWireGot Stocks?Got Stock Tips?Green Car StocksGreen Energy StocksGreen On The StreetHomeRunStocksMissionIRMissionIR MediaMissionPRMissionSMRNetworkNewsWireQualityStocks MediaQStocksQualityStocksQualityStocks TwitsSeriousTradersSmallCapRelationsSocial Media RelationsStock BeatsStocks To Buy NowTerrificStocksTiny GemsTip.usTouchdownStocksDaily ToutTraderPower

About The QualityStocks Daily

The QualityStocks Daily Newsletter brings you the latest company News and Profiles featuring the "Top Movers and Shakers" from the Small Cap Market each trading day. QualityStocks is committed to bring our subscribers Public companies in our Newsletter Section "Free of Charge" based on Percentage gained, Momentum, Press, and or Company Fundamentals.

Why do we spotlight companies for Free?
We Want To bring our subscribers the top movers in an unbiased setting.

"Homework Eliminates Mistakes"
Please never invest in a company anyone profiles unless you do the proper research and due diligence.

QualityStocks is compensated by the companies in The QS Company Corner. These companies will include a disclaimer with the amount and term of compensation.

Please consult the QualityStocks Market Basics Section on our site.